

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## A multi-centre longitudinal study of fluid and neuroimaging BIOmarkers of AXonal injury after Traumatic Brain Injury: the BIO-AX-TBI study protocol

|                               |  |
|-------------------------------|--|
| Journal:                      | <i>BMJ Open</i>  |
| Manuscript ID                 | bmjopen-2020-042093  |
| Article Type:                 | Protocol   |
| Date Submitted by the Author: | 24-Jun-2020  |
| Complete List of Authors:     | Graham, Neil; Imperial College London, Department of Brain Sciences; UK DRI Centre for Care Research and Technology<br>Zimmerman, Karl; Imperial College London, Department of Brain Sciences; UK DRI Centre for Care Research and Technology<br>Bertolini, Guido; Mario Negri Institute for Pharmacological Research<br>Magnoni, Sandra; Policlinco Maggiore<br>Oddo, Mauro; CHUV Lausanne University Hospital, Department of Intensive Care Medicine<br>Zetterberg, Henrik; UCL Queen Square Institute of Neurology<br>Moro, Federico; Mario Negri Institute for Pharmacological Research<br>Novelli, Deborah; Mario Negri Institute for Pharmacological Research<br>Heslegrave, Amanda; UCL Queen Square Institute of Neurology<br>Fleming, Joanne; Mario Negri Institute for Pharmacological Research<br>Garbero, Elena; Mario Negri Institute for Pharmacological Research<br>Abed-Maillard, Samia; CHUV Lausanne University Hospital, Department of Intensive Care Medicine<br>Gradisek, Primoz; University Medical Center, Clinical Dpt of Anaesthesiology and Intensive Therapy<br>Bernini, Adriano; CHUV Lausanne University Hospital, Department of Intensive Care Medicine<br>Sharp, David; Imperial College London, Department of Brain Sciences; UK DRI Centre for Care Research and Technology |
| Keywords:                     | TRAUMA MANAGEMENT, Neurological injury < NEUROLOGY, Biochemistry < NATURAL SCIENCE DISCIPLINES, Magnetic resonance imaging < RADIOLOGY & IMAGING   |
|                               |  |

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

**Full title:** A multi-centre longitudinal study of fluid and neuroimaging BIOMarkers of AXonal injury after Traumatic Brain Injury: the BIO-AX-TBI study protocol

**Authors:** Graham NSN<sup>\*1,2,3</sup>, Zimmerman KA<sup>\*1,2,3</sup>, Bertolini G<sup>4</sup>, Magnoni S<sup>5</sup>, Oddo M<sup>6</sup>, Zetterberg H<sup>7</sup>, Moro F<sup>4</sup>, Novelli D<sup>4</sup>, Heslegrave A<sup>7</sup>, Fleming JM<sup>4</sup>, Garbero E<sup>4</sup>, Abed Maillard Samia<sup>6</sup>, Gradisek P<sup>8</sup>, Bernini A<sup>6</sup>, Sharp DJ<sup>\*\*1,2,3</sup>.

\*joint first author, \*\*corresponding author

#### Author affiliations:

1. Department of Brain Sciences, Division of Medicine, Imperial College London, UK
2. UK Dementia Research Institute, Centre for Care, Research and Technology, UK
3. Centre for Injury Studies, Imperial College London, UK
4. Mario Negri Institute for Pharmacological Research, Milan, Italy
5. Policlinico Maggiore, Milan, Italy
6. Department of Intensive Care Medicine, Lausanne University Hospital, Lausanne, Switzerland
7. UCL Queen Square Institute of Neurology
8. University Medical Centre, Ljubljana, Slovenia

#### Corresponding author contact details:

Professor David Sharp | +44 (0)20 7594 7991 | david.sharp@imperial.ac.uk

The Computational, Cognitive and Clinical Neuroimaging Laboratory

3rd Floor, Burlington Danes Building

Hammersmith Hospital

Du Cane Road

London

W12 0NN

#### Author email addresses and ORCIDs:

Neil Graham: [neil.graham@imperial.ac.uk](mailto:neil.graham@imperial.ac.uk) <http://orcid.org/0000-0002-0183-3368>

Karl Zimmerman: [karl.zimmerman11@imperial.ac.uk](mailto:karl.zimmerman11@imperial.ac.uk) <https://orcid.org/0000-0003-1239-3414>

Guido Bertolini: [guido.bertolini@marionegri.it](mailto:guido.bertolini@marionegri.it)

Sandra Magnoni: [sdr.magnoni@gmail.com](mailto:sdr.magnoni@gmail.com)

Mauro Oddo: [mauro.oddo@chuv.ch](mailto:mauro.oddo@chuv.ch)

Henrik Zetterberg: [h.zetterberg@ucl.ac.uk](mailto:h.zetterberg@ucl.ac.uk)

Federico Moro: [federico.moro@marionegri.it](mailto:federico.moro@marionegri.it)

Deborah Novelli: [deborah.novelli@marionegri.it](mailto:deborah.novelli@marionegri.it)

1 Amanda Heselgrave: [a.heslegrave@ucl.ac.uk](mailto:a.heslegrave@ucl.ac.uk)

2  
3 Joanne Fleming: [joanne.fleming@marionegri.it](mailto:joanne.fleming@marionegri.it)

4  
5 Elena Garbero: [elena.garbero@marionegri.it](mailto:elena.garbero@marionegri.it)

6  
7 Samia Abed Maillard: [samia.abed-maillard@chuv.ch](mailto:samia.abed-maillard@chuv.ch)

8  
9 Primoz Gradisek: [primoz.gradisek@kclj.si](mailto:primoz.gradisek@kclj.si)

10 Adriano Bernini: [adriano.bernini@chuv.ch](mailto:adriano.bernini@chuv.ch)

11 David Sharp: [david.sharp@imperial.ac.uk](mailto:david.sharp@imperial.ac.uk) <http://orcid.org/0000-0003-4995-2240>

12  
13  
14  
15 **Keywords:**

16  
17  
18 Brain Injuries, Traumatic | Biomarkers | Craniocerebral Trauma | Cognition | Neuroimaging

19  
20  
21  
22 **Word count:** 3929

**Abstract:****INTRODUCTION AND AIMS:**

Traumatic brain injury (TBI) often results in persistent disability, due particularly to cognitive impairments. Outcomes remain difficult to predict but appear to relate to axonal injury. Several new approaches involving fluid and neuroimaging biomarkers show promise to sensitively quantify axonal injury. By assessing these longitudinally in a large cohort, we aim both to improve our understanding of the pathophysiology of TBI, and provide better tools to predict clinical outcome.

**METHODS AND ANALYSIS:**

BIO-AX-TBI is a prospective longitudinal study of fluid and neuroimaging biomarkers of axonal injury after moderate-severe TBI, currently being conducted across multiple European centres. We will provide a detailed characterisation of axonal injury after TBI, using fluid (such as plasma/microdialysate neurofilament light) and neuroimaging biomarkers (including diffusion tensor MRI), which will then be related to detailed clinical, cognitive and functional outcome measures. We aim to recruit at least 250 patients, including 40 with cerebral microdialysis performed, with serial assessments performed twice in the first ten days after injury, sub-acutely at ten days to six weeks, at six and twelve months after injury.

**ETHICS AND DISSEMINATION:**

The relevant ethical approvals have been granted by local Review Boards across multiple participating centres. The study findings will be disseminated to patients, healthcare professionals, academics and policymakers including through presentation at conferences and peer-reviewed publications. Data will be shared with approved researchers to provide further insights for patient benefit.

**TRIAL REGISTRATION NUMBER:**

NCT03534154

## ARTICLE SUMMARY

### Strengths and limitations of this study

- The BIO-AX-TBI observational study will characterise relationships of novel fluid and neuroimaging biomarkers of axonal injury to clinical outcomes over 12 months after moderate-severe traumatic brain injury
- Our study operates across multiple European centres with a core programme of work (including blood biomarkers and baseline MRI) supplemented in selected research sites by longitudinal MRI, advanced imaging sequences and cerebral microdialysis
- We will assess whether biomarkers (such as plasma neurofilament light, MRI brain atrophy and white matter damage) are suitable for surrogate clinical, cognitive and functional outcome measures, which could be employed in clinical trials of disease modifying treatments in pre-symptomatic populations
- We will use common data elements (CDE) to capture clinical, demographic and injury information, our data will be comparable across other large cohort studies of TBI validating our results in the international context
- In common with any longitudinal observational study there is a risk of loss to follow-up, which we assume and account for in our sample size calculations

### INTRODUCTION

Traumatic brain injury (TBI) often results in persistent disability due particularly to cognitive and psychiatric impairments.<sup>1</sup> The impact of these problems on everyday function and prediction of long-term outcomes is often assessed inadequately by standard clinical assessment and imaging techniques. Most survivors are young and have near-normal life expectancy.<sup>2</sup> Hence, the burden on public health and social care is substantial.<sup>3</sup> Improved methods of tracking progress and predicting outcomes are needed following TBI. These include clinical, neuropsychological, fluid biomarker and neuroimaging measures that could potentially be combined to yield important information. The proposed work aims to investigate clinical outcomes after TBI and identify the best way to track progress and predict outcomes.

Diffuse axonal injury after TBI results in damage to white matter connections and disruption of brain network structure and function. These changes are known to correlate with long clinical outcomes.<sup>4 5</sup> Previously it has been difficult to study the location and extent of this damage or its functional consequences. Now, using new multimodal techniques, the consequences of TBI on brain connectivity can be defined more clearly. Diffusion tensor imaging (DTI) allows structural damage to white matter connections to be identified after TBI. This technique allows us to assess whether damage to specific tracts results in a predictable cognitive deficit.<sup>6 7</sup>

1 In addition to structural brain imaging, functional magnetic resonance imaging (fMRI) can be used to provide  
2 complementary information about the consequences of white matter damage at different spatiotemporal scales  
3 following TBI. We have used this approach to provide important insights into the biological basis of cognitive  
4 impairment after TBI. Functional MRI studies of TBI have consistently demonstrated abnormal task-related  
5 activation within frontal and temporal lobes.<sup>8,9</sup> Understanding the effects of axonal injury on functional outcomes  
6 is essential to identify and predict cognitive impairment following TBI. We will use advanced MRI methods to  
7 investigate how best to identify the structural and functional effects of diffuse axonal injury and their relationship  
8 to clinical outcomes.  
9

10 Fluid biomarkers provide a complementary measure of axonal injury after TBI. Damage to neurons and glial cells  
11 can lead to increases in fluid biomarkers that are clinically informative.<sup>10-12</sup> For example, cytoskeletal proteins  
12 are released from damaged axons and can be detected in the blood.<sup>13,14</sup> Recent advances have identified a number  
13 of promising biomarkers with markedly increased sensitivity making it feasible to investigate and validate a blood  
14 biomarker of axonal injury.<sup>15</sup> In this study we will investigate the relationship between plasma and neuroimaging  
15 markers of axonal injury following TBI to determine whether a blood biomarker of axonal injury is valid and  
16 also study the time-course of cognitive changes after TBI and their relationship to underlying brain injury.  
17

18 Cerebral microdialysis can provide particularly important insights into the origin of biomarkers for axonal injury.  
19 Cytoskeletal proteins from damaged axons are released into the cerebral interstitial fluid compartment during  
20 acute axonal injury, from where they can be directly sampled.<sup>16,17</sup> This can be achieved with high temporal  
21 resolution, providing a method for assessing the effects of therapeutic interventions.<sup>18</sup> Recent findings indicate  
22 that microdialysis-based measurement of tau and NFL in the brain extracellular space may be a useful way to  
23 assess the severity of axonal injury in the acute setting. High initial microdialysis levels of tau are correlated with  
24 worse clinical outcomes.<sup>16</sup> In addition, microdialysis concentrations of tau are proportional to abnormalities in  
25 diffusion tensor MRI, indicating that both measures reflect the same underlying axonal injury.<sup>17</sup> In contrast, the  
26 relationship between local NFL concentrations and axonal injury has yet not been explored, although our  
27 preliminary data indicate that brain extracellular levels of NFL remain elevated for a longer period than tau and  
28 show heterogenous dynamics that may reflect the progression of underlying axonal injury.  
29

30 The study links closely with a multi-centre European collaboration of clinical outcomes after TBI (Collaborative  
31 REsearch on ACute Traumatic Brain Injury in intensiVe Care Medicine in Europe, 'CREACTIVE',  
32 NCT02004080). Integrating with this project allows us to collect common data across a large number of TBI  
33 patients, which allows work to be validated in relation to international experience.<sup>19,20</sup> CREATiVE is part of  
34 the International Initiative for Traumatic Brain Injury Research (InTBIR), a large international collaborative  
35 effort to advance clinical TBI research. We will particularly integrate neuroimaging, blood biomarker and  
36



neuropsychological assessments. Quality of life and clinical measures will also be used in order to identify functional outcomes of patients during the tracking of their cognition.

## GOALS AND OBJECTIVES OF BIO-AX-TBI

### **Acute injury measures and relationship to clinical outcome (work package 1)**

We aim to identify the most informative plasma biomarker(s) of the severity of axonal injury using a large multi-centre cohort of adult moderate-severe TBI patients. We will characterise their time course focusing on neurofilament light (NFL) and tau, and relate these to MRI measures of axonal injury in the early phase post injury. We will assess how these measures contribute to the prediction of clinical, cognitive and functional outcome at twelve months.

### **Longitudinal neuroimaging and detailed cognitive assessment (work package 2)**

In a subgroup of the recruited patients we will use advanced MRI and longitudinal assessments to provide a more detailed description of the relationship between the plasma biomarkers and outcome after TBI. We will test whether advanced diffusion measures correlate with plasma biomarkers and whether early plasma biomarker levels predict neurodegeneration measured by progressive atrophy after TBI.

### **Microdialysis assessment of biomarker dynamics (work package 3)**

In a second subgroup of patients we will combine microdialysis, neuroimaging and plasma sampling of axonal proteins to provide a deeper understanding of the mechanisms of axonal injury progression and use this approach to investigate the axonal origin of the plasma biomarkers.

### **Validation in large cohort and computed tomography head neuroimaging analysis (work package 4)**

The outputs of the above will be used to select the plasma biomarkers of axonal injury that best predict clinical outcome. These biomarkers will be validated by exploiting a large sample (~n=1000) of TBI patients collected within the CREATIVE project. In addition, the relationship between the CT head scan appearances and plasma biomarkers will be investigated using machine learning analysis to test whether CT head scans contain specific features of axonal injury and whether these features can be used to help predict outcome.

## METHODS AND ANALYSIS

### **Overall design**

BIO-AX-TBI is a prospective multi-centre observational study of TBI clinical outcomes. Patients with acute moderate-severe TBI, as per the Mayo Classification of injury severity,<sup>21</sup> will be recruited from trauma centres taking part in the study and followed-up longitudinally over a year, with assessments taking place acutely, at 10 days – 6 weeks, 6 months and 12 months post injury.

## Participating centres and Recruitment Progress

BIO-AX-TBI started recruitment in 30<sup>th</sup> November 2017 and involves eight different trauma centres across Europe. These include: Lausanne University Hospital, Switzerland, St George's and St Mary's Hospitals, London, University Medical Centre, Ljubljana, Slovenia, and, in Italy, Carregi University Hospital, Santa Chiara Hospital, Trento, Niguarda Hospital and Policlinico in Milan (Figure 1).

### Figure 1. Map: European Major Trauma Centres Participating in BIO-AX-TBI

Figure 1. Locations of eight major trauma centres recruiting patients to the BIO-AX-TBI study, including multiple sites across the UK, Switzerland, Italy, and Slovenia. Map data copyright 2020 Google, INEGI, ORION-ME, used under fair-use licence.

Our targets are to recruit at least 250 patients in total, including 40 with invasive cerebral microdialysis. As of February 2020, 311 patients after moderate-severe TBI have been recruited into the study (Figure 2).

### Figure 2. Study Recruitment Status




Figure 2. Cumulative number of patients recruited into the BIO-AX-TBI study since its initiation, a total of 311 participants as of June 2020.

## Entry into the study

Patients suitable for the research will be identified by the clinicians and research team working with the patients in trauma centres across participating sites. Those satisfying the inclusion and exclusion criteria will be approached and given written and verbal information about the study and invited to participate (Table 1).

**Table 1. Inclusion and Exclusion Criteria**

| Inclusion criteria                        | Exclusion criteria  |
|---|---|
| Moderate-severe TBI (Mayo classification) | For whole study:  |
| Age 18-80                                 | Previous significant TBI (requiring hospitalisation),   |
|   | Moribund patients   |
|   | Cardiac arrests   |
|   | Inability or unwillingness to participate in study  |
|   | Prior significant neurological or psychiatric condition   |
|   | Previous significant disability from any cause  |
|   | For MRI: typical MRI contraindications of ferromagnetic implants in the body, claustrophobia, pregnancy |

Moderate-severe injuries will be identified as per the Mayo classification, if any of the following features are present: death due to the TBI, loss of consciousness of more than 30 minutes, post traumatic amnesia duration of more than 24 hours, lowest Glasgow Coma Scale of less than 13 in the first 24h hours, imaging abnormalities such as intracerebral haematoma, subdural, extradural, contusion, penetrating injury of dura, subarachnoid haemorrhage or brainstem injury.<sup>21</sup>

Individuals will have the opportunity to ask questions about the study. Questions will be asked to assess the individual's suitability for the study. Potential participants will be given at least 24 hours to consider the request prior to recruitment into the study. If the potential participant is suitable for the study, informed consent will be obtained.

If a patient is unable to provide fully informed consent we will assent with permission from next of kin or personal/nominated consultee, according to the national legislations. Patients that have been assented will be re-consented if they are subsequently able to provide full informed consent. The consent procedure will be carried out in strict compliance with related local/national legislation and, where applicable with GDPR. Any waivers of consent provided for by national public health legislation, e.g. where this is in the public interest, will be indicated. Subjects will be free to withdraw, or be withdrawn by their legal representative if appropriate, at any point in the study, and they need not state any reason.

### Structure of Assessments

The study is organised into separate work packages, reflecting differing longitudinal assessment programmes for those at recruiting sites (Table 1), as set-out in ‘goals and objectives’.

**Table 1. Work Packages in Participating Major Trauma Centres**

| Institution                     | City      | Country     | Work Package |
|---------------------------------|-----------|-------------|--------------|
| Careggi University Hospital     | Florence  | Italy       | 1            |
| Lausanne University Hospital    | Lausanne  | Switzerland | 3            |
| Niguarda Hospital               | Milan     | Italy       | 1            |
| Policlinico of Milan            | Milan     | Italy       | 2            |
| Santa Chiara Hospital           | Trento    | Italy       | 1            |
| St Mary's Hospital              | London    | UK          | 2            |
| St George's University Hospital | London    | UK          | 2            |
| University Medical Centre       | Ljubljana | Slovenia    | 1            |

Patients participating in work package 1 will have clinical and demographic information collected acutely using the electronic case report form (eCRF). Blood samples will be collected twice in the first ten days after injury, and at subsequent visits at 10 days – 6 weeks, and around 12 months. Standard MRI scanning will be performed at 10 days-6 weeks only. Outcomes will be assessed at 6 months via telephone and 12 months via a face-to-face assessment. If face-to-face follow-ups are not possible then remote follow-up will be attempted e.g. through telephone consultation.

Work package 2 comprises a more detailed programme of assessment. As per WP1, the eCRF will be completed acutely alongside blood tests twice in the first 10 days after injury. Advanced MRI will be performed at the 10 days-6 weeks study visit, alongside blood biomarker assessment and clinical/cognitive outcome assessment. Blood biomarker, advanced MRI and outcome assessment will be repeated face-to-face at 6 and 12 months after injury.

Work package 3 involves the addition of cerebral microdialysis assessments acutely during the inpatient admission. Blood biomarker assessment is more frequent, up to twice per 24-hour period during cerebral microdialysis. Standard MRI is performed alongside blood biomarkers at 10 days-6 weeks. Face to face outcome assessments are performed at 6 and 12 months post injury.

Work package 4 is an analysis-only package involving comparing our data to a broader sample of TBI patients collected within the CREATIVE project, including neuroimaging data.

Healthy volunteers will have a single timepoint MRI assessment and blood biomarker assessment using the same protocol as patients. Assessments of cognition, motor function, psychiatric outcome and sleep quality will be

performed. 15 healthy control subjects per centre (total n=105) will be recruited, matched to TBI patients for age and sex.

### Electronic Case Report Form

Participant details will be collected using an electronic structured case report form ('Prosafe') requiring population of TBI common data elements.<sup>19</sup> This was developed as part of the large multi-centre GiViTI (*Gruppo Italiano per la Valutazione degli Interventi in Terapia Intensiva* – Italian Group for the Evaluation of Interventions in Intensive Care Medicine) ICU network in Italy,<sup>22</sup> and provides a framework to collect high quality records that meet strict criteria. The software facilitates data entry at research sites, pseudonymisation, and centralisation across sites for analysis. Data is entered for all participants, including a limited healthy volunteer eCRF for control data collection.

### Clinical, Cognitive and Functional Outcome Assessment

Study participants will undergo a number of tests of clinical outcome and cognitive function as they recover from injury (Table 2).

**Table 2. Outcome Assessments in Patients after TBI**

| OUTCOME MEASURE  | ASSESSMENT TIMEPOINT |          |           |
|--|----------------------|----------|-----------|
|  | 10 days to 6 weeks   | 6 months | 12 months |
| <b>Functional outcome</b>  |                      |          |           |
| Glasgow Outcome Scale – Extended (GOSE)                                    | WP 1,2,3             | WP 1,2,3 | WP 1,2,3  |
| Frontal Systems Behaviour Scale (FrSBe)*                                   |                      | WP 2,3   | WP 2,3    |
| Lille apathy ratings scale (LARS)*   |                      | WP 2,3   | WP 2,3    |
| Mayo-Portland Adaptability Inventory (MPAI-4)*                             | WP 2,3               | WP 2,3   | WP 2,3    |
| <b>Cognitive function</b>  |                      |          |           |
| Stroop test (Delis-Kaplan Executive Function System)                       | WP 2,3               | WP 2,3   | WP 2,3    |
| Trail making tests A and B.  | WP 2,3               | WP 2,3   | WP 2,3    |
| Montreal cognitive assessment (MOCA)                                       |                      |          | WP 1,2,3  |
| Computerised Go/No-Go, Corsi blocks and N-back                             |                      |          | WP 1,2,3  |
| Repeatable Battery for the Assessment of Neuropsychological status (RBANS) | WP 2,3               | WP 2,3   | WP 2,3    |
| <b>Motor function</b>  |                      |          |           |
| Box and block test of motor function.                                      |                      |          | WP 1,2,3  |
| Functional ambulatory category questionnaire                               |                      |          | WP 1,2,3  |
| <b>Quality of life</b>   |                      |          |           |
| Quality of life after brain injury – Overall Scale (QOLIBRI-OS)            | WP 1,2,3             | WP 1,2,3 | WP 1,2,3  |
| <b>Psychiatric outcome</b>   |                      |          |           |
| Hospital Anxiety and Depression Scale                                      |                      |          | WP 1,2,3  |
| Post-traumatic stress disorder checklist for DSM-V (PCL-5)                 |                      |          | WP 1,2,3  |

|                                      |  |          |          |
|--------------------------------------|--|----------|----------|
| <b>Sleep quality</b>                 |  |          |          |
| Insomnia Severity Index              |  |          | WP 1,2,3 |
| <b>Rehabilitation treatment</b>      |  |          |          |
| Rehabilitation pathway questionnaire |  | WP 1,2,3 | WP 1,2,3 |

\* administered to patient and caregiver

Standardised pen and paper neuropsychological tests and a number of questionnaires designed to assess functional outcomes after TBI will be used. Assessments will coincide with biomarker assessment timepoints. Healthy volunteer assessments will be performed to facilitate comparison (Table 3).

**Table 3. Cognitive and Functional Assessments in Healthy Volunteers**

|  |
|--|
| <b>Cognitive function</b>                              |
| Stroop test (Delis-Kaplan Executive Function System)** |
| Trail making tests A and B. **                         |
| Montreal cognitive assessment (MOCA)                   |
| Computerised Go/No-Go, Corsi blocks and N-back         |
| <b>Motor function</b>                                  |
| Box and block test of motor function.                  |
| Functional ambulatory category questionnaire           |
| <b>Psychiatric outcome</b>                             |
| Hospital Anxiety and Depression Scale                  |
| <b>Sleep quality</b>                                   |
| Insomnia Severity Index                                |

\*\* Excluding centres performing WP1 only

Where appropriate, family or close friends will also be asked to complete caregiver questionnaires to provide an objective measure of perceived impairments and functional outcomes. Assessments will be performed by an appropriately trained investigator. These may include: Lille apathy ratings scale (LARS), Frontal Systems Behaviour Scale (FrSBe) and the Mayo-Portland Adaptability Inventory (MPAI-4).

### Blood biomarkers

Blood samples ( $\approx 12\text{mL}$  on each occasion) will be taken on different number of occasions depending on the work package the patient is recruited to. BIO-AX-TBI samples comprise: 2x K3 EDTA (6 ml, for plasma biomarkers) and where ethical approvals permit, 1x further K3 EDTA (6ml, whole blood for DNA analysis). The aligned CREATIVE study involves the following sample collection: 1x bottle of each sodium citrate (3.5 ml), serum z-clot activator (5ml) and K3 EDTA (6 ml). BIO-AX-TBI samples are taken twice in the first ten days after TBI. In those participants undergoing microdialysis, a K3 EDTA 6ml sample may be taken up to a maximum of 12

hourly for 14 samples. Sample processing involves centrifugation at 2000-2500g for 10-20 minutes at 4 degrees centigrade.

Blood and other human samples (i.e. microdialysis samples) will be labelled using a human readable barcode system. We will process, store and dispose of all tissue in accordance with all applicable legal and regulatory requirements. All blood samples will be processed within two hours of collection. Microdialysis samples will be stored at local facilities and sent to the central lab afterwards. Patient identity is kept confidential.

Samples will be kept in locked storage and may be stored for up to 15 years from the end of the study. Participants can withdraw their consent for their samples to be stored or used at any point. If they choose to do so, and notify us, their samples will not be used for any further research and will be destroyed in accordance with all applicable legal and regulatory requirements. Analysis of blood samples will allow circulating factors related to outcomes after TBI to be identified. These may include: neurofilament light (NFL), tau, glial fibrillary acidic protein (GFAP), ubiquitin C-terminal hydrolase 1 (UCHL1) and protein S100 (S100B).

Anonymous samples may be analysed either within Imperial (ICL), University College London (UCL) or in other institutions or laboratories, including those outside the UK and EU. In participating centres where the relevant ethical approvals are granted, we will process the blood samples to allow for assessment of known genetic factors and factors that will be eventually known in the future that may influence clinical outcome after TBI. We will store DNA samples without any personally identifiable information for future analysis. Patients will not be informed of the results of genetic analysis. These DNA samples will be stored in an anonymised fashion in a secure -80°C freezer.

### **Cerebral Microdialysis**

Patients will be monitored with cerebral microdialysis as part of standard patient care and according to local protocols.<sup>23</sup> This will start immediately after injury and continue until clinically indicated (normally 5-7 days). 100 kD cut-off MDialysis AB microdialysis catheters will be surgically implanted through a burr hole in white matter regions that appear normal on CT (mainly in the right, non-dominant frontal lobe). In patients with frontal contusions, catheters will be placed distant to intra-cerebral lesions. A standard 2 mm non-contrast brain CT scan will be taken within 24 hours to verify correct catheter placement. CT scan images will be co-registered with MRI.

Colloids such as dextran or albumin solutions will be added to the standard perfusion fluid to increase both fluid and protein recovery, as indicated by the manufacturer, and as recently reported.<sup>24</sup> A standard flow rate of 0.3 ml/min will be used in all patients, allowing hourly recovery of brain extracellular fluid (about 20 ml). A subset of samples will be routinely analysed for lactate, pyruvate, glycerol, glutamate and glucose at bedside



using a portable analyser (Iscus Flex, MDialysis AB, Stockholm, Sweden) to measure in vivo changes of cerebral metabolites. These data will be displayed real time for clinical use as indicated by published guidelines (16). Six vials (4 hourly during collection) will be immediately frozen and stored after collection for the measurement of biomarker concentrations (eg. tau and NFL). These samples will be centralised to UCL laboratory.

Microdialysis and brain physiology data, including mean arterial pressure, intracranial pressure, cerebral perfusion pressure and core temperature, will be continuously recorded as part of a multimodal monitoring system and transferred to excel sheets. Additional information, including lab and arterial blood gas analysis data, hourly vital signs and ventilation parameters, if applicable, will be recorded.

## MRI assessment

Participants will undergo an MRI scanning session comprising structural and functional MRI scans (see Table 4). The timing of imaging assessments depends on the work package in which a given participant is enrolled. Participants will undergo a set of structural MRI scans including T1 (for high-resolution detail), susceptibility weighted imaging (SWI) and T2 FLAIR (for detecting other abnormalities), T2 mapping (for detecting oedema), and diffusion MRI (for measuring white matter and white matter damage). Functional MRI (fMRI) will be used to measure regional brain activity over time. Functional MRI will be performed with the subject lying at rest in the scanner (resting-state fMRI). These different types of MRI provide complementary information about the location of brain injury and the effects of these injuries on brain function and cognition.

Repeated MRI assessment are necessary as damage after TBI can be progressive and the brain scanning provides information about the timing of this progression. We will investigate how the MRI signature of axonal injury develops over time and how brain shrinkage atrophy evolves. Our aim is to use these measures as prognostic indicators and also as imaging biomarkers to evaluate novel therapeutic interventions.

**Table 4. MRI Assessment Details**

|                | London  | Niguarda             | Lausanne  | Ljubljana | Florence | Milan                | Trento            |
|----------------|---------|----------------------|-----------|-----------|----------|----------------------|-------------------|
| <b>Scanner</b> |         |                      |           |           |          |                      |                   |
| manufacturer   | Siemens | Philips              | Siemens   | Siemens   | Siemens  | Philips              | GE                |
| model          | Verio   | Achieva              | Skyra Fit | Trio Tim  | Aera     | Achieva              | Optima            |
| field strength | 3T      | 1.5T                 | 3T        | 3T        | 1.5T     | 3T                   | 1.50%             |
| software       | MR B17  | Rel. 5<br>Neuroradio | MR B19    | MR B19    | VE11a    | Rel. 5<br>Neuroradio | DV25.1_R03_1802.a |



| Voxel size (mm)        |             |             |             |             |             |             |             |             |
|------------------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|
| MPRAGE                 | 1x1x1       | 1x1x1       | 1x1x1       | 1x1x1       | 1x1x1       | 1x1x1       | 1x1x1       | 0.5x0.5x1   |
| DTI                    | 2x2x2       | 2x2x2       | 2x2x2       | 2x2x2       | 2x2x2       | 2x2x2       | 2x2x2       | 1x2x2       |
| rs-fMRI                | 3x3x3       | 3x3x3       | 3x3x3       | 3x3x3       | 3x3x3       | 3x3x3       | 3x3x3       | 3x3x3       |
| FLAIR                  | 1x1x1       | 1.2x1.2x0.7 | 0.5x0.5x1   | 1x1x1       | 0.5x0.5x1   | 1x1x1       | 1x1x1       | 1.2x0.5x0.5 |
| SWI                    | 0.6x0.5x1.2 | 1x1x1       | 0.3x0.3x1.6 | 0.6x0.5x1.2 | 0.8x0.8x0.8 | 0.5x0.5x1.2 | 0.5x0.5x1.2 | 0.5x0.5x1   |
| <b>DTI parameters</b>  |             |             |             |             |             |             |             |             |
| receiver coil channels | 32          | 8           | 64          | 32          | 20          | 32          | 32          | 8           |
| directions             | 64          | 64          | 64          | 64          | 64          | 64          | 64          | 60          |
| b-value                | 1000        | 1000        | 1000        | 1000        | 1000        | 1000        | 1000        | 1000        |

## Sample size

We estimate that a minimum of 140 patients will be necessary to test the contribution of DTI to prognostic modelling (type-1 error=0.05, power=0.95). Loss to follow-up is an important but unpredictable element and we have allowed for up to a further 25-30% loss to follow-up by aiming to enrol 250 patients in the study. Our estimates indicated that a minimum of 12 imaging controls will be necessary for each centre.

To assess atrophy progression after TBI in work package two, our calculations indicate a sample size of 10 per group is needed to detect a group difference in brain atrophy over 6 months with effect size of  $f=0.32$ , assuming 95% and a correlation between repeated measures = 0.9.

We have based the WP3 sample size ( $n=40$ ) on previous similar microdialysis studies that have used 15-20 subjects and shown correlations between biomarker and imaging measures. With a sample size of 40 we should be adequately powered for this analysis, as well as being able to take into account the additional variability related to different centres.

## Data management

Data and all appropriate documentation will be stored for a minimum of 10 years after the completion of the study. This is to enable subsequent analyses with new network analysis techniques as they are developed. All

study data will be stored, analysed and published in anonymised format. Fluid biomarkers will be stored at UCL and neuroimaging data at Imperial College London.

As part of a large European multi-centre study of clinical outcomes following TBI, pseudonymised clinical data will be shared with the CREATIVe network. The research program of CREATIVe has a strong emphasis on data collection, aimed at obtaining all available relevant clinical data of the patients admitted to the major trauma centres in the CREATIVe network, in this instance, all patients admitted to participating MTCs in London. Data to be collected on these patients will include pseudonymised follow-up data, related to post-acute patient care and patient outcomes. The pseudonymised data will be uploaded to an encrypted database on a network which is accessible to the CREATIVe team. This database has full https encryption with a certificate from an official authority. Both the database and the application into which the data are loaded are run from dedicated servers. The data collected for this component of the study will be centrally stored by the CREATIVe team for 20 years from the closing date of the study. At that time point, all data collected for this study will be definitively deleted. If these data are considered at that time to be particularly relevant for scientific purposes, a specific authorisation to continue their use will be issued to the competent local/national relevant ethical boards/bodies.

## **ETHICAL CONSIDERATIONS**

### **Consent & Mental Capacity issues**

Periods of post-traumatic amnesia (PTA) or low consciousness level are commonly observed after TBI, and during this period, patients may not have mental capacity give valid informed consent. An important element of the proposed work cannot otherwise be answered by only studying patients with capacity.

The proposed investigation methods are routinely used in the assessment of TBI patients in an intensive care setting and are safe, as long as normal safety precautions are taken in the case of MRI. We have used this safely to investigate the causes of poor clinical outcome after TBI (18).

At the time of initial contact by the clinical team an assessment of the patient's capacity will be made in relation to entering the study in accordance with national legislation. If the patient is not found to have capacity then they will be enrolled, if appropriate, following the national rules. Patients will not be coerced if assent is not given. If during the study the patient subsequently objects to participation in a portion of the study s/he will be withdrawn. Advanced statements regarding participation in research will be sought and respected.

When the patient is no longer in post-traumatic amnesia or a state of impaired consciousness, we will repeat the consent procedure and the patient will be free to withdraw from the study or continue participation.

Our study will involve negligible risk to the patient and will not significantly interfere with freedom of action or privacy or be unduly invasive or restrictive. The primary inconvenience to the patient is to cooperate with an MRI scan which can take up to 60 minutes and, for some patients, be noisy, uncomfortable and claustrophobic. We will consider using light oral sedation such as benzodiazepines (diazepam) if this is judged to be helpful. There is also a risk to patients if they have ferromagnetic metal on their person and all the usual MRI safety checks and procedures will be undertaken to minimise this risk. Uncooperative and unconscious patients at the time of MRI (e.g. intensive care treated patients) will receive sedation and will be monitored for vital signs under the surveillance of the treating physician and according to local protocols for MRI in critically ill patients.

## RESEARCH PARTICIPANT INVOLVEMENT & DISSEMINATION PLAN

Patients and research participants were involved in the formulation of our programme via regular participant involvement opportunities at the sponsoring institution (Imperial College London). We plan to disseminate our research findings to the widest possible audience via a number of channels, including publication of papers in peer-reviewed journals, participant involvement events, press releases online via a study website (see [bioaxtbi.com](http://bioaxtbi.com)), and through sharing of data with approved researchers. Anonymised data will be shared with approved researchers at the end of the study to help further improve understanding of axonal injury in TBI.

## CONCLUSION

Our results will guide the incorporation of plasma biomarkers, microdialysis and advanced MRI measures into medical practice in the management of TBI. We aim to provide robust evidence about the best measures for the early assessment of axonal injury and disease progression. The validation of neuroimaging and plasma biomarkers for axonal injury would be tremendously valuable, as reliable measures will facilitate prognostication after injury, as well as guiding the selection and evaluation of treatments.

## ACKNOWLEDGEMENTS

1  
2  
3 The investigators would like to acknowledge the kind support of our patients and healthy volunteers for taking  
4 part in the study, as well as our funders and all those involved in facilitating the project.  
5  
6  
7

## CONFLICTS OF INTEREST

8  
9  
10  
11 HZ has served at advisory boards for Eli Lilly, Roche Diagnostics and Pharmasum Therapeutics, and is a co-  
12 founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the  
13 University of Gothenburg. The other authors have no potential conflicts to declare.  
14  
15  
16  
17

## DATA STATEMENT

18  
19  
20  
21  
22 BIO-AX-TBI data will be made available in an anonymised form for other approved researchers to use on  
23 completion of the study.  
24  
25  
26

## AUTHOR CONTRIBUTIONS

27  
28  
29  
30 NG, KZ and DJS drafted the manuscript. GB, SM, MO, HZ, FM, DN, AH, JF, EG, SA, PG and AB critically  
31 reviewed and revised it. All authors contributed to the design, intellectual content and approved the final version.  
32  
33  
34

## FUNDING

35  
36  
37  
38  
39 The study is funded by the ERA-NET Neuron Cofund (grant MR/R004528/1), part of the European Research  
40 Projects on External Insults to the Nervous System call, within the Horizon 2020 funding framework. The work  
41 was supported by an Alzheimer's Research UK Clinical Research Fellowship awarded to NG, and by the UK  
42 Dementia Research Institute (DRI) Care Research and Technology Centre (NG/DJS), an National Institute of  
43 Health Research (NIHR) Professorship (NIHR-RP-011-048) awarded to D.J.S. and by the NIHR Clinical  
44 Research Facility and Biomedical Research Centre (BRC) at Imperial College Healthcare NHS Trust. The  
45 research was also supported the Medical Research Council through a Clinician Scientist Fellowship awarded to  
46 D.J.S.  
47  
48  
49  
50  
51  
52  
53

## IMAGE RIGHTS

54  
55  
56  
57  
58 Map data copyright 2020 Google, INEGI, ORION-ME, used under fair-use licence.  
59  
60

## REFERENCES

- 1
- 2
- 3 1. Whitnall L, McMillan TM, Murray GD, et al. Disability in young people and adults after head injury: 5-7 year
- 4 follow up of a prospective cohort study. *J Neurol Neurosurg Psychiatry* 2006;77(5):640-5. doi:
- 5 10.1136/jnnp.2005.078246 [published Online First: 2006/04/15]
- 6
- 7 2. Thornhill S, Teasdale GM, Murray GD, et al. Disability in young people and adults one year after head injury:
- 8 prospective cohort study. *Bmj-Brit Med J* 2000;320(7250):1631-5. doi: 10.1136/bmj.320.7250.1631
- 9 [published Online First: 2000/06/16]
- 10
- 11 3. Thurman DJ, Alverson C, Dunn KA, et al. Traumatic brain injury in the United States: A public health
- 12 perspective. *J Head Trauma Rehabil* 1999;14(6):602-15. doi: 10.1097/00001199-199912000-00009
- 13 [published Online First: 2000/02/15]
- 14
- 15 4. Salmond CH, Menon DK, Chatfield DA, et al. Diffusion tensor imaging in chronic head injury survivors:
- 16 correlations with learning and memory indices. *Neuroimage* 2006;29(1):117-24. doi:
- 17 10.1016/j.neuroimage.2005.07.012 [published Online First: 2005/08/09]
- 18
- 19 5. Kinnunen KM, Greenwood R, Powell JH, et al. White matter damage and cognitive impairment after
- 20 traumatic brain injury. *Brain* 2011;134(Pt 2):449-63. doi: 10.1093/brain/awq347 [published Online
- 21 First: 2011/01/05]
- 22
- 23 6. Scheid R, Walther K, Guthke T, et al. Cognitive sequelae of diffuse axonal injury. *Arch Neurol*
- 24 2006;63(3):418-24. doi: 10.1001/archneur.63.3.418 [published Online First: 2006/03/15]
- 25
- 26 7. Sidaros A, Engberg AW, Sidaros K, et al. Diffusion tensor imaging during recovery from severe traumatic
- 27 brain injury and relation to clinical outcome: a longitudinal study. *Brain* 2008;131(Pt 2):559-72. doi:
- 28 10.1093/brain/awm294 [published Online First: 2007/12/18]
- 29
- 30 8. Sharp DJ, Bonnelle V, De Boissezon X, et al. Distinct frontal systems for response inhibition, attentional
- 31 capture, and error processing. *Proc Natl Acad Sci U S A* 2010;107(13):6106-11. doi:
- 32 10.1073/pnas.1000175107 [published Online First: 2010/03/12]
- 33
- 34 9. Bonnelle V, Ham TE, Leech R, et al. Salience network integrity predicts default mode network function after
- 35 traumatic brain injury. *Proc Natl Acad Sci U S A* 2012;109(12):4690-5. doi: 10.1073/pnas.1113455109
- 36 [published Online First: 2012/03/07]
- 37
- 38 10. Shahim P, Gren M, Liman V, et al. Serum neurofilament light protein predicts clinical outcome in traumatic
- 39 brain injury. *Scientific reports* 2016;6:36791. doi: 10.1038/srep36791 [published Online First:
- 40 2016/11/08]
- 41
- 42 11. Thelin E, Al Nimer F, Frostell A, et al. A Serum Protein Biomarker Panel Improves Outcome Prediction in
- 43 Human Traumatic Brain Injury. *J Neurotrauma* 2019;36(20):2850-62. doi: 10.1089/neu.2019.6375
- 44 [published Online First: 2019/05/11]
- 45
- 46 12. Hossain I, Mohammadian M, Takala RSK, et al. Early Levels of Glial Fibrillary Acidic Protein and
- 47 Neurofilament Light Protein in Predicting the Outcome of Mild Traumatic Brain Injury. *J Neurotrauma*
- 48 2019;36(10):1551-60. doi: 10.1089/neu.2018.5952 [published Online First: 2018/11/30]
- 49
- 50 13. Bernick C, Zetterberg H, Shan G, et al. Longitudinal Performance of Plasma Neurofilament Light and Tau in
- 51 Professional Fighters: The Professional Fighters Brain Health Study. *J Neurotrauma* 2018;35(20):2351-
- 52 56. doi: 10.1089/neu.2017.5553 [published Online First: 2018/04/04]
- 53
- 54 14. Shahim P, Tegner Y, Marklund N, et al. Neurofilament light and tau as blood biomarkers for sports-related
- 55 concussion. *Neurology* 2018;90(20):e1780-e88. doi: 10.1212/WNL.0000000000005518 [published
- 56 Online First: 2018/04/15]
- 57
- 58 15. Kuhle J, Barro C, Andreasson U, et al. Comparison of three analytical platforms for quantification of the
- 59 neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and
- 60 Simoa. *Clin Chem Lab Med* 2016;54(10):1655-61. doi: 10.1515/cclm-2015-1195 [published Online First:
- 2016/04/14]

17. Magnoni S, Mac Donald CL, Esparza TJ, et al. Quantitative assessments of traumatic axonal injury in human brain: concordance of microdialysis and advanced MRI. *Brain* 2015;138(Pt 8):2263-77. doi: 10.1093/brain/awv152 [published Online First: 2015/06/19]
18. Bouzat P, Sala N, Suys T, et al. Cerebral metabolic effects of exogenous lactate supplementation on the injured human brain. *Intensive care medicine* 2014;40(3):412-21. doi: 10.1007/s00134-013-3203-6 [published Online First: 2014/01/31]
19. Maas AI, Harrison-Felix CL, Menon D, et al. Common data elements for traumatic brain injury: recommendations from the interagency working group on demographics and clinical assessment. *Arch Phys Med Rehabil* 2010;91(11):1641-9. doi: 10.1016/j.apmr.2010.07.232 [published Online First: 2010/11/04]
20. Maas AIR, Menon DK, Adelson PD, et al. Traumatic brain injury: integrated approaches to improve prevention, clinical care, and research. *Lancet Neurol* 2017;16(12):987-1048. doi: 10.1016/S1474-4422(17)30371-X [published Online First: 2017/11/11]
21. Malec JF, Brown AW, Leibson CL, et al. The mayo classification system for traumatic brain injury severity. *J Neurotrauma* 2007;24(9):1417-24. doi: 10.1089/neu.2006.0245 [published Online First: 2007/09/26]
22. Apolone G, Brazzi L, Pesce C. Multicenter study on the treatment and outcome of patients admitted to intensive care units in Italy. Presentation of the research project and the study protocol. GiViTI (Gruppo Italiano per la Valutazione degli interventi in Terapia Intensiva). *Minerva Anestesiol* 1992;58(12):1297-303. [published Online First: 1992/12/01]
23. Oddo M, Hutchinson PJ. Understanding and monitoring brain injury: the role of cerebral microdialysis. *Intensive Care Med* 2018;44(11):1945-48. doi: 10.1007/s00134-017-5031-6 [published Online First: 2017/12/25]
24. Giorgi-Coll S, Thelin EP, Lindblad C, et al. Dextran 500 Improves Recovery of Inflammatory Markers: An In Vitro Microdialysis Study. *J Neurotrauma* 2020;37(1):106-14. doi: 10.1089/neu.2019.6513 [published Online First: 2019/07/13]

# BMJ Open

## A multi-centre longitudinal study of fluid and neuroimaging BIOmarkers of AXonal injury after Traumatic Brain Injury: the BIO-AX-TBI study protocol

|                               |  |
|-------------------------------|--|
| Journal:                      | <i>BMJ Open</i>  |
| Manuscript ID                 | bmjopen-2020-042093.R1   |
| Article Type:                 | Protocol   |
| Date Submitted by the Author: | 29-Aug-2020  |
| Complete List of Authors:     | <p>Graham, Neil; Imperial College London, Department of Brain Sciences; UK DRI Centre for Care Research and Technology</p> <p>Zimmerman, Karl; Imperial College London, Department of Brain Sciences; UK DRI Centre for Care Research and Technology</p> <p>Bertolini, Guido; IRCCS-"Mario Negri" Institute for Pharmacological Research, Public Health, Villa Camozzi, Via Camozzi, Ranica, Bergamo, IT 24020</p> <p>Magnoni, Sandra; Santa Chiara Hospital, Department of Anesthesia and intensive Care</p> <p>Oddo, Mauro; CHUV Lausanne University Hospital, Department of Intensive Care Medicine</p> <p>Zetterberg, Henrik; UCL Queen Square Institute of Neurology, Department of Neurodegenerative Disease; University of Gothenburg Sahlgrenska Academy, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology</p> <p>Moro, Federico; IRCCS-"Mario Negri" Institute for Pharmacological Research, Public Health, Villa Camozzi, Via Camozzi, Ranica, Bergamo, IT 24020</p> <p>Novelli, Deborah; IRCCS-"Mario Negri" Institute for Pharmacological Research, Public Health, Villa Camozzi, Via Camozzi, Ranica, Bergamo, IT 24020</p> <p>Heslegrave, Amanda; UCL Queen Square Institute of Neurology</p> <p>Chieragato, Arturo; ASST Grande Ospedale Metropolitano Niguarda, Neuroranimazione</p> <p>Fainardi, Enrico; University of Firenze, Department of Experimental and Clinical Sciences, Careggi University Hospital</p> <p>Fleming, Joanne; IRCCS-"Mario Negri" Institute for Pharmacological Research, Public Health</p> <p>Garbero, Elena; IRCCS-"Mario Negri" Institute for Pharmacological Research, Public Health, Villa Camozzi, Via Camozzi, Ranica, Bergamo, IT 24020</p> <p>Abed-Maillard, Samia; CHUV Lausanne University Hospital, Department of Intensive Care Medicine</p> <p>Gradisek, Primoz; University Medical Center, Clinical Dpt of Anaesthesiology and Intensive Therapy</p> <p>Bernini, Adriano; CHUV Lausanne University Hospital, Department of Intensive Care Medicine</p> <p>Sharp, David; Imperial College London, Division of Brain Sciences</p> |



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

|                                   |  |
|-----------------------------------|--|
| <b>Primary Subject Heading:</b>   | Neurology  |
| <b>Secondary Subject Heading:</b> | Public health, Intensive care, Emergency medicine  |
| <b>Keywords:</b>                  | TRAUMA MANAGEMENT, Neurological injury < NEUROLOGY, Biochemistry < NATURAL SCIENCE DISCIPLINES, Magnetic resonance imaging < RADIOLOGY & IMAGING |
|                                   |  |







I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

**Full title:** A multi-centre longitudinal study of fluid and neuroimaging BIOMarkers of AXonal injury after Traumatic Brain Injury: the BIO-AX-TBI study protocol

**Authors:** Graham NSN<sup>\*1,2,3</sup>, Zimmerman KA<sup>\*1,2,3</sup>, Bertolini G<sup>4</sup>, Magnoni S<sup>5</sup>, Oddo M<sup>6</sup>, Zetterberg H<sup>7,8,9,10</sup>, Moro F<sup>4</sup>, Novelli D<sup>4</sup>, Heslegrave A<sup>7,8</sup>, Chieragato A<sup>11</sup>, Fainardi E<sup>12</sup>, Fleming JM<sup>4</sup>, Garbero E<sup>4</sup>, Abed Maillard S<sup>6</sup>, Gradisek P<sup>13</sup>, Bernini A<sup>6</sup>, Sharp DJ<sup>\*\*1,2,3</sup>.

\*joint first author, \*\*corresponding author

#### Author affiliations:

1. Department of Brain Sciences, Division of Medicine, Imperial College London, UK
2. UK Dementia Research Institute, Centre for Care, Research and Technology, UK
3. Centre for Injury Studies, Imperial College London, UK
4. Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy
5. Department of Anesthesia and Intensive Care, Santa Chiara Hospital, Trento, Italy
6. Department of Intensive Care Medicine, Lausanne University Hospital, Lausanne, Switzerland
7. Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK
8. Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden
9. Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden
10. UK Dementia Research Institute at UCL, London, UK
11. Neurointensive Care Unit, Niguarda Hospital, Milan
12. Department of Experimental and Clinical Sciences, Careggi University Hospital, University of Firenze, Florence, Italy
13. University Medical Centre, Ljubljana, Slovenia

#### Corresponding author contact details:

Professor David Sharp | +44 (0)20 7594 7991 | david.sharp@imperial.ac.uk

The Computational, Cognitive and Clinical Neuroimaging Laboratory

3rd Floor, Burlington Danes Building

Hammersmith Hospital

Du Cane Road

London

W12 0NN

#### Author email addresses and ORCIDs:

1

2<sup>1</sup> Neil SN Graham: neil.graham@imperial.ac.uk <http://orcid.org/0000-0002-0183-3368>

3<sup>2</sup> Karl A Zimmerman: karl.zimmerman11@imperial.ac.uk <https://orcid.org/0000-0003-1239-3414>

4<sup>3</sup> Guido Bertolini: guido.bertolini@marionegri.it

5<sup>4</sup> Sandra Magnoni: sdr.magnoni@gmail.com

6<sup>5</sup> Mauro Oddo: mauro.oddo@chuv.ch

7<sup>6</sup> Henrik Zetterberg: h.zetterberg@ucl.ac.uk

8<sup>7</sup> Federico Moro: federico.moro@marionegri.it

9<sup>8</sup> Deborah Novelli: deborah.novelli@marionegri.it

10<sup>9</sup> Amanda Heselgrave: a.heslegrave@ucl.ac.uk

11<sup>10</sup> Joanne M Fleming: joanne.fleming@marionegri.it

12<sup>11</sup> Arturo Chierogato: arturo.chierogato@gmail.com

13<sup>12</sup> Enrico Fainardi: henryfai@tin.it

14<sup>13</sup> Elena Garbero: elena.garbero@marionegri.it

15<sup>14</sup> Samia Abed Maillard: samia.abed-maillard@chuv.ch

16<sup>15</sup> Primoz Gradisek: primoz.gradisek@kclj.si

17<sup>16</sup> Adriano Bernini: adriano.bernini@chuv.ch

18<sup>17</sup> David J Sharp: david.sharp@imperial.ac.uk <http://orcid.org/0000-0003-4995-2240>

19<sup>18</sup>  
20<sup>19</sup> **Keywords:**

21<sup>20</sup>  
22<sup>21</sup> Brain Injuries, Traumatic | Biomarkers | Craniocerebral Trauma | Cognition | Neuroimaging

23<sup>22</sup>  
24<sup>23</sup> **Word count:** 4808

25<sup>24</sup>26<sup>25</sup>27<sup>26</sup>28<sup>27</sup>29<sup>28</sup>30<sup>29</sup>31<sup>30</sup>32<sup>31</sup>33<sup>32</sup>34<sup>33</sup>35<sup>34</sup>36<sup>35</sup>37<sup>36</sup>38<sup>37</sup>39<sup>38</sup>40<sup>39</sup>

**Abstract:****INTRODUCTION AND AIMS:**

Traumatic brain injury (TBI) often results in persistent disability, due particularly to cognitive impairments. Outcomes remain difficult to predict but appear to relate to axonal injury. Several new approaches involving fluid and neuroimaging biomarkers show promise to sensitively quantify axonal injury. By assessing these longitudinally in a large cohort, we aim both to improve our understanding of the pathophysiology of TBI, and provide better tools to predict clinical outcome.

**METHODS AND ANALYSIS:**

BIO-AX-TBI is a prospective longitudinal study of fluid and neuroimaging biomarkers of axonal injury after moderate-severe TBI, currently being conducted across multiple European centres. We will provide a detailed characterisation of axonal injury after TBI, using fluid (such as plasma/microdialysate neurofilament light) and neuroimaging biomarkers (including diffusion tensor MRI), which will then be related to detailed clinical, cognitive and functional outcome measures. We aim to recruit at least 250 patients, including 40 with cerebral microdialysis performed, with serial assessments performed twice in the first ten days after injury, sub-acutely at ten days to six weeks, at six and twelve months after injury.

**ETHICS AND DISSEMINATION:**

The relevant ethical approvals have been granted by the following ethics committees: in London, by the Camberwell St Giles Research Ethics Committee; in Policlinico (Milan), by the Comitato Etico Milano Area 2; in Niguarda (Milan), by the Comitato Etico Milano Area 3; in Careggi (Florence), by the Comitato Etico Regionale per la Sperimentazione Clinica della Regione Toscana, Sezione area vasta centro; in Trento, by the Trento Comitato Etico per le Sperimentazioni Cliniche, Azienda Provinciale per i Servizi Sanitari della Provincia autonoma di Trento; in Lausanne, by the Commission cantonale (VD) d'éthique de la recherche sur l'être humain (CER-VD); in Ljubljana, by the National Medical Ethics Committee at the Ministry of Health of the Republic of Slovenia. The study findings will be disseminated to patients, healthcare professionals, academics and policymakers including through presentation at conferences and peer-reviewed publications. Data will be shared with approved researchers to provide further insights for patient benefit.

**TRIAL REGISTRATION NUMBER:**

NCT03534154

## ARTICLE SUMMARY

### Strengths and limitations of this study

- The BIO-AX-TBI observational study will characterise relationships of novel fluid and neuroimaging biomarkers of axonal injury to clinical outcomes over 12 months after moderate-severe traumatic brain injury
- Our study operates across multiple European centres with a core programme of work (including blood biomarkers and baseline MRI) supplemented in selected research sites by longitudinal MRI, advanced imaging sequences and cerebral microdialysis
- We will assess whether biomarkers such as plasma neurofilament light, MRI brain atrophy and white matter damage are suitable surrogate outcome measures for possible use in clinical trials
- We will use common data elements (CDE) to capture clinical, demographic and injury information, our data will be comparable across other large cohort studies of TBI validating our results in the international context
- In common with any longitudinal observational study there is a risk of loss to follow-up, which we assume and account for in our sample size calculations

## INTRODUCTION

Traumatic brain injury (TBI) often results in persistent disability due particularly to cognitive and psychiatric impairments.<sup>1</sup> The impact of these problems on everyday function and prediction of long-term outcomes is often assessed inadequately by standard clinical assessment and imaging techniques. Most survivors are young and have near-normal life expectancy.<sup>2</sup> Hence, the burden on public health and social care is substantial.<sup>3</sup> Improved methods of tracking progress and predicting outcomes are needed following TBI. These include clinical, neuropsychological, fluid biomarker and neuroimaging measures that could potentially be combined to yield important information. The proposed work aims to investigate clinical outcomes after TBI and identify the best way to track progress and predict outcomes.

Diffuse axonal injury after TBI results in damage to white matter connections and disruption of brain network structure and function. These changes are known to correlate with long clinical outcomes.<sup>4 5</sup> Previously it has been difficult to study the location and extent of this damage or its functional consequences. Now, using new multimodal techniques, the consequences of TBI on brain connectivity can be defined more clearly. Diffusion tensor imaging (DTI) allows structural damage to white matter connections to be identified after TBI. This technique allows us to assess whether damage to specific tracts results in a predictable cognitive deficit.<sup>6 7</sup>

1 In addition to structural brain imaging, functional magnetic resonance imaging (fMRI) can be used to provide  
2 complementary information about the consequences of white matter damage at different spatiotemporal scales  
3 following TBI. We have used this approach to provide important insights into the biological basis of cognitive  
4 impairment after TBI. Functional MRI studies of TBI have consistently demonstrated abnormal task-related  
5 activation within frontal and temporal lobes.<sup>8,9</sup> Understanding the effects of axonal injury on functional outcomes  
6 is essential to identify and predict cognitive impairment following TBI. We will use advanced MRI methods to  
7 investigate how best to identify the structural and functional effects of diffuse axonal injury and their relationship  
8 to clinical outcomes.  
9

10 Fluid biomarkers provide a complementary measure of axonal injury after TBI. Damage to neurons and glial cells  
11 can lead to increases in fluid biomarkers that are clinically informative.<sup>10-12</sup> For example, cytoskeletal proteins  
12 are released from damaged axons and can be detected in the blood.<sup>13,14</sup> Recent advances have identified a number  
13 of promising biomarkers with markedly increased sensitivity making it feasible to investigate and validate a blood  
14 biomarker of axonal injury.<sup>15</sup> In this study we will investigate the relationship between plasma and neuroimaging  
15 markers of axonal injury following TBI to determine whether a blood biomarker of axonal injury is valid and  
16 also study the time-course of cognitive changes after TBI and their relationship to underlying brain injury.  
17

18 Cerebral microdialysis can provide particularly important insights into the origin of biomarkers for axonal injury.  
19 Cytoskeletal proteins from damaged axons are released into the cerebral interstitial fluid compartment during  
20 acute axonal injury, from where they can be directly sampled.<sup>16,17</sup> This can be achieved with high temporal  
21 resolution, providing a method for assessing the effects of therapeutic interventions.<sup>18</sup> Recent findings indicate  
22 that microdialysis-based measurement of tau and NFL in the brain extracellular space may be a useful way to  
23 assess the severity of axonal injury in the acute setting. High initial microdialysis levels of tau are correlated with  
24 worse clinical outcomes.<sup>16</sup> In addition, microdialysis concentrations of tau are proportional to abnormalities in  
25 diffusion tensor MRI, indicating that both measures reflect the same underlying axonal injury.<sup>17</sup> In contrast, the  
26 relationship between local NFL concentrations and axonal injury has yet not been explored, although our  
27 preliminary data indicate that brain extracellular levels of NFL remain elevated for a longer period than tau and  
28 show heterogenous dynamics that may reflect the progression of underlying axonal injury.  
29

30 The study links closely with a multi-centre European collaboration of clinical outcomes after TBI (Collaborative  
31 REsearch on ACute Traumatic Brain Injury in intensiVe Care Medicine in Europe, 'CREACTIVE',  
32 NCT02004080). Integrating with this project allows us to collect common data across a large number of TBI  
33 patients, which allows work to be validated in relation to international experience.<sup>19,20</sup> CREATiVE is part of  
34 the International Initiative for Traumatic Brain Injury Research (InTBIR), a large international collaborative  
35 effort to advance clinical TBI research. We will particularly integrate neuroimaging, blood biomarker and  
36 neuropsychological assessments. Quality of life and clinical measures will also be used in order to identify  
37 functional outcomes of patients during the tracking of their cognition.

## GOALS AND OBJECTIVES OF BIO-AX-TBI

### Acute injury measures and relationship to clinical outcome (work package 1)

We aim to identify the most informative plasma biomarker(s) of the severity of axonal injury using a large multi-centre cohort of adult moderate-severe TBI patients. We will characterise their time course focusing on neurofilament light (NFL) and tau, and relate these to MRI measures of axonal injury in the early phase post injury. We will assess how these measures contribute to the prediction of clinical, cognitive and functional outcome at twelve months.

### Longitudinal neuroimaging and detailed cognitive assessment (work package 2)

In a subgroup of the recruited patients we will use advanced MRI and longitudinal assessments to provide a more detailed description of the relationship between the plasma biomarkers and outcome after TBI. We will test whether advanced diffusion measures correlate with plasma biomarkers and whether early plasma biomarker levels predict neurodegeneration measured by progressive atrophy after TBI.

### Microdialysis assessment of biomarker dynamics (work package 3)

In a second subgroup of patients we will combine microdialysis, neuroimaging and plasma sampling of axonal proteins to provide a deeper understanding of the mechanisms of axonal injury progression and use this approach to investigate the axonal origin of the plasma biomarkers.

### Validation in large cohort and computed tomography head neuroimaging analysis (work package 4)

The outputs of the above will be used to select the plasma biomarkers of axonal injury that best predict clinical outcome. These biomarkers will be validated by exploiting a large sample (~n=1000) of TBI patients collected within the CREATIVe project. In addition, the relationship between the CT head scan appearances and plasma biomarkers will be investigated using machine learning analysis to test whether CT head scans contain specific features of axonal injury and whether these features can be used to help predict outcome.

## METHODS AND ANALYSIS

### Overall design

BIO-AX-TBI is a prospective multi-centre observational study of TBI clinical outcomes. Patients with acute moderate-severe TBI, as per the Mayo Classification of injury severity,<sup>21</sup> will be recruited from trauma centres



taking part in the study and followed-up longitudinally over a year, with assessments taking place acutely, at 10 days – 6 weeks, 6 months and 12 months post injury.

### Participating centres and Recruitment Progress

BIO-AX-TBI started recruitment in 30<sup>th</sup> November 2017 and involves eight different trauma centres across Europe. These include: Lausanne University Hospital, Switzerland, St George's and St Mary's Hospitals, London, University Medical Centre, Ljubljana, Slovenia, and, in Italy, Carregi University Hospital, Santa Chiara Hospital, Trento, Niguarda Hospital and Policlinico in Milan.

Our targets are to recruit at least 250 patients in total, including 40 with invasive cerebral microdialysis. As of June 2020, 311 patients after moderate-severe TBI have been recruited into the study (Figure 1), with recruitment ongoing in order to meet our target in the cerebral microdialysis group.

### Entry into the study

Patients suitable for the research will be identified by the clinicians and research team working with the patients in trauma centres across participating sites. Those satisfying the inclusion and exclusion criteria will be approached and given written and verbal information about the study and invited to participate (Table 1).

**Table 1. Inclusion and Exclusion Criteria**

| Inclusion criteria                        | Exclusion criteria   |
|---|--|
| Moderate-severe TBI (Mayo classification) | For whole study:<br>Previous significant TBI (requiring hospitalisation),<br>Moribund patients<br>Cardiac arrests<br>Inability or unwillingness to participate in study<br>Prior significant neurological or psychiatric condition<br>Previous significant disability from any cause |
| Age 18-80                                 | For MRI: typical MRI contraindications of ferromagnetic implants in the body, claustrophobia, pregnancy  |

Moderate-severe injuries will be identified as per the Mayo classification, if any of the following features are present: death due to the TBI, loss of consciousness of more than 30 minutes, post traumatic amnesia duration of more than 24 hours, lowest Glasgow Coma Scale of less than 13 in the first 24h hours, imaging abnormalities



such as intracerebral haematoma, subdural, extradural, contusion, penetrating injury of dura, subarachnoid haemorrhage or brainstem injury.<sup>21</sup>

Individuals will have the opportunity to ask questions about the study. Questions will be asked to assess the individual's suitability for the study. Potential participants will be asked to consider the request for a period of 24 hours prior to recruitment into the study. If the potential participant is suitable for the study, informed consent will be obtained. Our goal is to recruit patients as early after trauma as is practical, and ideally within ten days of injury in order to facilitate acute blood biomarker assessment.

If a patient is unable to provide fully informed consent we will assent with permission from next of kin or personal/nominated consultee, according to the national legislations. Patients that have been assented will be re-consented if they are subsequently able to provide full informed consent. The consent procedure will be carried out in strict compliance with related local/national legislation and, where applicable with GDPR. Any waivers of consent provided for by national public health legislation, e.g. where this is in the public interest, will be indicated. Subjects will be free to withdraw, or be withdrawn by their legal representative if appropriate, at any point in the study, and they need not state any reason.

### Structure of Assessments

The study is organised into separate work packages, reflecting differing longitudinal assessment programmes for those at recruiting sites (Table 1), as set-out in 'goals and objectives'.

**Table 1. Work Packages in Participating Major Trauma Centres**

| Institution                     | City      | Country     | Work Package |
|---------------------------------|-----------|-------------|--------------|
| Careggi University Hospital     | Florence  | Italy       | 1            |
| Lausanne University Hospital    | Lausanne  | Switzerland | 3            |
| Niguarda Hospital               | Milan     | Italy       | 1            |
| Policlinico of Milan            | Milan     | Italy       | 2            |
| Santa Chiara Hospital           | Trento    | Italy       | 1            |
| St Mary's Hospital              | London    | UK          | 2            |
| St George's University Hospital | London    | UK          | 2            |
| University Medical Centre       | Ljubljana | Slovenia    | 1            |

Patients participating in work package 1 will have clinical and demographic information collected acutely using the electronic case report form (eCRF). Blood samples will be collected twice in the first ten days after injury, and at subsequent visits at 10 days – 6 weeks, and around 12 months. Standard MRI scanning will be performed at 10 days-6 weeks only. Outcomes will be assessed at 6 months via telephone and 12 months via a face-to-face

1 assessment. If face-to-face follow-ups are not possible then remote follow-up will be attempted e.g. through  
2<sup>1</sup> telephone consultation.

3  
4  
5 Work package 2 comprises a more detailed programme of assessment. As per WP1, the eCRF will be completed  
6 acutely alongside blood tests twice in the first 10 days after injury. Advanced MRI will be performed at the 10  
7 days-6 weeks study visit, alongside blood biomarker assessment and clinical/cognitive outcome assessment.  
8 Blood biomarker, advanced MRI and outcome assessment will be repeated face-to-face at 6 and 12 months after  
9 injury.  
10  
11  
12

13  
14  
15 Work package 3 involves the addition of cerebral microdialysis assessments acutely during the inpatient  
16 admission. Blood biomarker assessment is more frequent, up to twice per 24-hour period during cerebral  
17 microdialysis. Standard MRI is performed alongside blood biomarkers at 10 days-6 weeks. Face to face outcome  
18 assessments are performed at 6 and 12 months post injury.  
19  
20  
21

22  
23  
24 Work package 4 is an analysis-only package involving comparing our data (WP1-3) to a broader sample of TBI  
25 patients collected within the related CReACTIVE project, including neuroimaging data. This work package does  
26 not involve collection of new data or biological samples. Two main analyses are planned: first, to compare clinical  
27 features, biomarkers and outcomes in patients in the BIOAXTBI cohort with the broader CReACTIVE  
28 population, where these are in-common, and establish how well findings from WP1-3 generalise in the larger  
29 group. Second, a machine learning analysis will be performed to establish whether CT brain imaging data in this  
30 large cohort can reliably predict outcomes.  
31  
32  
33

34  
35  
36  
37 Healthy volunteers will have a single timepoint MRI assessment and blood biomarker assessment using the same  
38 protocol as patients. Assessments of cognition, motor function, psychiatric outcome and sleep quality will be  
39 performed. 15 healthy control subjects per centre (total n=105) will be recruited, matched to TBI patients for age  
40 and sex.  
41  
42  
43

#### 44 45 46 **Electronic Case Report Form**

47  
48  
49 Participant details will be collected using an electronic structured case report form ('Prosafe') requiring  
50 population of TBI common data elements.<sup>19</sup> This was developed as part of the large multi-centre GiViTI (*Gruppo*  
51 *Italiano per la Valutazione degli Interventi in Terapia Intensiva* – Italian Group for the Evaluation of  
52 Interventions in Intensive Care Medicine) ICU network in Italy,<sup>22</sup> and provides a framework to collect high  
53 quality records that meet strict criteria. The software facilitates data entry at research sites, pseudonymisation,  
54 and centralisation across sites for analysis. Data is entered for all participants, including a limited healthy  
55 volunteer eCRF for control data collection.  
56  
57  
58  
59  
60

## Clinical, Cognitive and Functional Outcome Assessment

Study participants will undergo a number of tests of clinical outcome and cognitive function as they recover from injury (Table 2).

**Table 2. Outcome Assessments in Patients after TBI**

| OUTCOME MEASURE  | ASSESSMENT TIMEPOINT |          |           |
|--|----------------------|----------|-----------|
|  | 10 days to 6 weeks   | 6 months | 12 months |
| <b>Functional outcome</b>  |                      |          |           |
| Glasgow Outcome Scale – Extended (GOSE)                                    | WP 1,2,3             | WP 1,2,3 | WP 1,2,3  |
| Frontal Systems Behaviour Scale (FrSBe)*                                   |                      | WP 2,3   | WP 2,3    |
| Lille apathy ratings scale (LARS)*   |                      | WP 2,3   | WP 2,3    |
| Mayo-Portland Adaptability Inventory (MPAI-4)*                             | WP 2,3               | WP 2,3   | WP 2,3    |
| <b>Cognitive function</b>  |                      |          |           |
| Stroop test (Delis-Kaplan Executive Function System)                       | WP 2,3               | WP 2,3   | WP 2,3    |
| Trail making tests A and B.  | WP 2,3               | WP 2,3   | WP 2,3    |
| Montreal cognitive assessment (MOCA)                                       |                      |          | WP 1,2,3  |
| Computerised Go/No-Go, Corsi blocks and N-back                             |                      |          | WP 1,2,3  |
| Repeatable Battery for the Assessment of Neuropsychological status (RBANS) | WP 2,3               | WP 2,3   | WP 2,3    |
| <b>Motor function</b>  |                      |          |           |
| Box and block test of motor function.                                      |                      |          | WP 1,2,3  |
| Functional ambulatory category questionnaire                               |                      |          | WP 1,2,3  |
| <b>Quality of life</b>   |                      |          |           |
| Quality of life after brain injury – Overall Scale (QOLIBRI-OS)            | WP 1,2,3             | WP 1,2,3 | WP 1,2,3  |
| <b>Psychiatric outcome</b>   |                      |          |           |
| Hospital Anxiety and Depression Scale                                      |                      |          | WP 1,2,3  |
| Post-traumatic stress disorder checklist for DSM-V (PCL-5)                 |                      |          | WP 1,2,3  |
| <b>Sleep quality</b>   |                      |          |           |
| Insomnia Severity Index  |                      |          | WP 1,2,3  |
| <b>Rehabilitation treatment</b>  |                      |          |           |
| Rehabilitation pathway questionnaire                                       |                      | WP 1,2,3 | WP 1,2,3  |

\* administered to patient and caregiver

Standardised pen and paper neuropsychological tests and a number of questionnaires designed to assess functional outcomes after TBI will be used. Assessments will coincide with biomarker assessment timepoints. Healthy volunteer assessments will be performed to facilitate comparison (Table 3).

**Table 3. Cognitive and Functional Assessments in Healthy Volunteers**

|  |
|--|
| <b>Cognitive function</b>                              |
| Stroop test (Delis-Kaplan Executive Function System)** |

|  |
|--|
| Trail making tests A and B. **                   |
| 1 Montreal cognitive assessment (MOCA)           |
| 2 Computerised Go/No-Go, Corsi blocks and N-back |
| 3 <b>Motor function</b>                          |
| 4 Box and block test of motor function.          |
| 5 Functional ambulatory category questionnaire   |
| 6  |
| 7 <b>Psychiatric outcome</b>                     |
| 8 Hospital Anxiety and Depression Scale          |
| 9  |
| 10 <b>Sleep quality</b>                          |
| 11 Insomnia Severity Index                       |

112 \*\* Excluding centres performing WP1 only

13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Where appropriate, family or close friends will also be asked to complete caregiver questionnaires to provide an objective measure of perceived impairments and functional outcomes. Assessments will be performed by an appropriately trained investigator. These may include: Lille apathy ratings scale (LARS), Frontal Systems Behaviour Scale (FrSBe) and the Mayo-Portland Adaptability Inventory (MPAI-4).

### 9 **Blood biomarkers**

10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Blood samples ( $\approx 12\text{mL}$  on each occasion) will be taken on different number of occasions depending on the work package the patient is recruited to. BIO-AX-TBI samples comprise: 2x K3 EDTA (6 ml, for plasma biomarkers) and where ethical approvals permit, 1x further K3 EDTA (6ml, whole blood for DNA analysis). The aligned CREATIVE study involves the following sample collection: 1x bottle of each sodium citrate (3.5 ml), serum z-clot activator (5ml) and K3 EDTA (6 ml). BIO-AX-TBI samples are taken twice in the first ten days after TBI. In those participants undergoing microdialysis, a K3 EDTA 6ml sample may be taken up to a maximum of 12 hourly for 14 samples. Sample processing involves centrifugation at 2000-2500g for 10-20 minutes at 4 degrees centigrade.

20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Blood and other human samples (i.e. microdialysis samples) will be labelled using a human readable barcode system. We will process, store and dispose of all tissue in accordance with all applicable legal and regulatory requirements. All blood samples will be processed within two hours of collection. Microdialysis samples will be stored at local facilities and sent to the central lab afterwards. Patient identity is kept confidential.

25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Samples will be kept in locked storage and may be stored for up to 15 years from the end of the study. Participants can withdraw their consent for their samples to be stored or used at any point. If they choose to do so, and notify us, their samples will not be used for any further research and will be destroyed in accordance with all applicable legal and regulatory requirements. Analysis of blood samples will allow circulating factors related to outcomes after TBI to be identified. These may include: neurofilament light (NFL), tau, glial fibrillary acidic protein (GFAP), ubiquitin C-terminal hydrolase 1 (UCHL1) and protein S100 (S100B). Fluid biomarker analyses will be

1 performed at UCL using a digital ELISA technique, using a Quanterix Simoa analyser to provide ultrasensitive  
2<sup>1</sup> assessment of concentrations.  
3  
4

5 Anonymous samples may be analysed either within Imperial (ICL), University College London (UCL) or in other  
6<sup>1</sup> institutions or laboratories, including those outside the UK and EU. In participating centres where the relevant  
7<sup>2</sup> ethical approvals are granted, we will process the blood samples to allow for assessment of known genetic factors  
8<sup>3</sup> and factors that will be eventually known in the future that may influence clinical outcome after TBI. We will  
9<sup>4</sup> store DNA samples without any personally identifiable information for future analysis. Patients will not be  
10<sup>5</sup> informed of the results of genetic analysis. These DNA samples will be stored in an anonymised fashion in a  
11<sup>6</sup> secure -80°C freezer. Genetic analyses may include APOE genotype assessment and/or generation of an  
12<sup>7</sup> individualised polygenic risk score for neurodegeneration, using a microarray targeting SNPs related to  
13<sup>8</sup> neurodegenerative disease.<sup>23</sup>  
14<sup>9</sup>  
15<sup>10</sup>  
16<sup>11</sup>  
17<sup>12</sup>  
18<sup>13</sup>  
19<sup>14</sup>

### 20<sup>15</sup> **Cerebral Microdialysis**

21<sup>16</sup> Patients will be monitored with cerebral microdialysis as part of standard patient care and according to local  
22<sup>17</sup> protocols.<sup>24</sup> This will start immediately after injury and continue until clinically indicated (normally 5-7 days).  
23<sup>18</sup> 100 kD cut-off MDialysis AB microdialysis catheters will be surgically implanted through a burr hole in white  
24<sup>19</sup> matter regions that appear normal on CT (mainly in the right, non-dominant frontal lobe). In patients with frontal  
25<sup>20</sup> contusions, catheters will be placed distant to intra-cerebral lesions. A standard 2 mm non-contrast brain CT scan  
26<sup>21</sup> will be taken within 24 hours to verify correct catheter placement. CT scan images will be co-registered with  
27<sup>22</sup> MRI.  
28<sup>23</sup>  
29<sup>24</sup>  
30<sup>25</sup>  
31<sup>26</sup>  
32<sup>27</sup>  
33<sup>28</sup>  
34<sup>29</sup>  
35<sup>30</sup>  
36<sup>31</sup>  
37<sup>32</sup>  
38<sup>33</sup>

39<sup>34</sup> Colloids such as dextran or albumin solutions will be added to the standard perfusion fluid to increase both fluid  
40<sup>35</sup> and protein recovery, as indicated by the manufacturer, and as recently reported.<sup>25</sup> A standard flow rate of 0.3  
41<sup>36</sup> ml/min will be used in all patients, allowing hourly recovery of brain extracellular fluid (about 20 ml). A  
42<sup>37</sup> subset of samples will be routinely analysed for lactate, pyruvate, glycerol, glutamate and glucose at bedside  
43<sup>38</sup> using a portable analyser (Iscus Flex, MDialysis AB, Stockholm, Sweden) to measure in vivo changes of cerebral  
44<sup>39</sup> metabolites. These data will be displayed real time for clinical use as indicated by published guidelines (16). Six  
45<sup>40</sup> vials (4 hourly during collection) will be immediately frozen and stored after collection for the measurement of  
46<sup>41</sup> biomarker concentrations (eg. tau and NFL). These samples will be centralised to UCL laboratory.  
47<sup>42</sup>  
48<sup>43</sup>  
49<sup>44</sup>  
50<sup>45</sup>  
51<sup>46</sup>  
52<sup>47</sup>  
53<sup>48</sup>  
54<sup>49</sup>  
55<sup>50</sup>  
56<sup>51</sup>  
57<sup>52</sup>  
58<sup>53</sup>  
59<sup>54</sup>  
60<sup>55</sup>

Microdialysis and brain physiology data, including mean arterial pressure, intracranial pressure, cerebral  
perfusion pressure and core temperature, will be continuously recorded as part of a multimodal monitoring system  
and transferred to excel sheets. Additional information, including lab and arterial blood gas analysis data, hourly  
vital signs and ventilation parameters, if applicable, will be recorded.

## 1 MRI assessment

2  
3 Participants will undergo an MRI scanning session comprising structural and functional MRI scans (see Table  
4 4). The timing of imaging assessments depends on the work package in which a given participant is enrolled.  
5  
6 Participants will undergo a set of structural MRI scans including T1 (for high-resolution detail), susceptibility  
7 weighted imaging (SWI) and T2 FLAIR (for detecting other abnormalities), T2 mapping (for detecting oedema),  
8 and diffusion MRI (for measuring white matter and white matter damage). Functional MRI (fMRI) will be used  
9 to measure regional brain activity over time. Functional MRI will be performed with the subject lying at rest in  
10 the scanner (resting-state fMRI). These different types of MRI provide complementary information about the  
11 location of brain injury and the effects of these injuries on brain function and cognition.  
12

13 Repeated MRI assessment are necessary as damage after TBI can be progressive and the brain scanning provides  
14 information about the timing of this progression. We will investigate how the MRI signature of axonal injury  
15 develops over time and how brain shrinkage atrophy evolves. Our aim is to use these measures as prognostic  
16 indicators and also as imaging biomarkers to evaluate novel therapeutic interventions.  
17

18  
19  
20  
21  
22  
23  
24  
25  
26  
27 **Table 4. MRI Assessment Details**

|                        | London      | Niguarda             | Lausanne    | Ljubljana   | Florence    | Milan                | Trento            |
|------------------------|-------------|----------------------|-------------|-------------|-------------|----------------------|-------------------|
| <b>Scanner</b>         |             |                      |             |             |             |                      |                   |
| manufacturer           | Siemens     | Philips              | Siemens     | Siemens     | Siemens     | Philips              | GE                |
| model                  | Verio       | Achieva              | Skyra Fit   | Trio Tim    | Aera        | Achieva              | Optima            |
| field strength         | 3T          | 1.5T                 | 3T          | 3T          | 1.5T        | 3T                   | 1.50%             |
| software               | MR B17      | Rel. 5<br>Neuroradio | MR B19      | MR B19      | VE11a       | Rel. 5<br>Neuroradio | DV25.1_R03_1802.a |
| <b>Voxelsize (mm)</b>  |             |                      |             |             |             |                      |                   |
| MPRAGE                 | 1x1x1       | 1x1x1                | 1x1x1       | 1x1x1       | 1x1x1       | 1x1x1                | 0.5x0.5x1         |
| DTI                    | 2x2x2       | 2x2x2                | 2x2x2       | 2x2x2       | 2x2x2       | 2x2x2                | 1x2x2             |
| rs-fMRI                | 3x3x3       | 3x3x3                | 3x3x3       | 3x3x3       | 3x3x3       | 3x3x3                | 3x3x3             |
| FLAIR                  | 1x1x1       | 1.2x1.2x0.7          | 0.5x0.5x1   | 1x1x1       | 0.5x0.5x1   | 1x1x1                | 1.2x0.5x0.5       |
| SWI                    | 0.6x0.5x1.2 | 1x1x1                | 0.3x0.3x1.6 | 0.6x0.5x1.2 | 0.8x0.8x0.8 | 0.5x0.5x1.2          | 0.5x0.5x1         |
| <b>DTI parameters</b>  |             |                      |             |             |             |                      |                   |
| receiver coil channels | 32          | 8                    | 64          | 32          | 20          | 32                   | 8                 |

|            |      |      |      |      |      |      |      |
|------------|------|------|------|------|------|------|------|
| directions | 64   | 64   | 64   | 64   | 64   | 64   | 60   |
| b-value    | 1000 | 1000 | 1000 | 1000 | 1000 | 1000 | 1000 |

## Sample size

The primary outcome measures are (1) change in diffusion tensor MRI measures over time [Time Frame: 10 days - 6 weeks, 6 months and 12 months], measured using fractional anisotropy; (2) Brain atrophy rates [Time Frame: 10 days - 6 weeks, 6 months and 12 months], using JD atrophy rates; (3) Change in levels of fluid biomarkers in blood [Time Frame: 0-5 days, 5-10 days, 10 days - 6 weeks, 6 months and 12 months] (4) Change in levels of fluid biomarkers in cerebral fluid [Time Frame: 48 hours to 7 days].

We estimate that a minimum of 140 patients will be necessary to test the contribution of DTI to prognostic modelling (type-1 error=0.05, power=0.95). Loss to follow-up is an important but unpredictable element and we have allowed for up to a further 25-30% loss to follow-up by aiming to enrol 250 patients in the study. Our estimates indicated that a minimum of 12 imaging controls will be necessary for each centre.

To assess atrophy progression after TBI in work package two, our calculations indicate a sample size of 10 per group is needed to detect a group difference in brain atrophy over 6 months with effect size of  $f=0.32$ , assuming 95% and a correlation between repeated measures = 0.9. Longitudinal brain atrophy rates will be calculated using the JD measure of atrophy rate generated using SPM 12 (UCL).<sup>26</sup>

Preliminary data suggests that moderate-severe TBI induces large changes in blood biomarker concentrations (eg. S100B, NFL). We estimate that the numbers required to show between group differences and relationships to outcome will be smaller than for DTI (1) or brain atrophy rates (2), on whose measures the study is primarily powered.

We have based the WP3 sample size ( $n=40$ ) on previous similar microdialysis studies that have used 15-20 subjects and shown correlations between biomarker and imaging measures. With a sample size of 40 we should be adequately powered for this analysis, as well as being able to take into account the additional variability related to different centres.

## Statistical analysis plan

### *Fluid biomarkers*



Blood biomarker trends will be described and compared between groups, as well as within individuals longitudinally. Distributions of variables will be assessed for normality and parametric/non-parametric tests used as needed for comparisons, with paired tests used within subjects for repeated measures. The relationship between fluid biomarkers and neuroimaging markers will be assessed, according to previously used approaches.<sup>27</sup> We will use linear regression to look at the relationship between blood biomarker levels and continuous outcomes, or logistic regression for binarised outcomes such as favourable / unfavourable recovery on the GOSE at 6 or 12 months. Cerebral microdialysis marker levels will be described over time and cross-compared to blood biomarker results, neuroimaging markers of axonal injury such as fractional anisotropy, and clinical outcomes, per Magnoni et al.<sup>16</sup>

### *Neuroimaging*

MRI and CT data will be centralised at Imperial College London. MRI reporting will be performed by neuroradiologists in London to allow comparison across sites, while CTs are reported locally. Individualised 'masks' will be manually drawn on structural MRI images to allow focal lesions to be excluded from later analyses, for each scanning session, for each study participant.

The following analyses will be performed:

- i) Diffusion tensor imaging – a tract based spatial statistics approach will be used to generate voxelwise maps of fractional anisotropy using well-established approaches in the TBI setting.<sup>5</sup> These will be compared between groups, allowing a description of axonal injury multiple levels including whole white matter, voxelwise and tractwise, as per Jolly et al.<sup>28</sup> To account for cross-site variability related to scanner, this will be included as a nuisance covariate in analyses. For cross-sectional diffusion imaging, for each scanning site, patient FA data will be normalised via a z-scoring approach to local controls carefully matched for age and sex. Z-scored FA data can be more reliably combined across sites, and larger group-wise analyses performed. Additionally, we will explore the use of a voxelwise algorithm designed to harmonise diffusion data across sites.<sup>29</sup>
- ii) Longitudinal atrophy assessment – we will use approaches previously established in the setting of moderate-severe TBI to generate individualised maps of brain volume change over time ('JD atrophy rate' maps) from serial T1 images.<sup>26</sup> Diffuse brain volume changes, such as related to neurodegeneration due to injury will be separated from the resolution of focal pathologies by the use of focal lesion masks, such that JD values in non-lesioned areas can be sampled and assessed. As each individual acts as their own 'control' longitudinally, we do anticipate a significant influence of scanner on atrophy rate assessment, and will quantify this effect using hierarchical partitioning of variance on linear regression.



- 1 iii) Resting state functional MRI – we will assess the effect of injury on brain network function cross  
2 sectionally and longitudinally using approaches previously applied to TBI, relating structural and  
3 functional connectivity.<sup>30</sup>  
4  
5  
6 iv) CT – we will apply several different approaches to test whether CT neuroimaging data can assist in  
7 outcome. We will test whether an automatic lesion segmentation algorithm trained in TBI patients  
8 produces outputs which reflect known clinical features and outcomes such as the GOSE.<sup>31</sup> We will  
9 train a multimodal neural network to take in scans at multiple timepoints within an individual's  
10 hospital admission, with auxiliary patient data, to predict outcome. We will assess supervised learning  
11 and will investigate methods to increase the model interpretability, such as heatmaps.  
12  
13  
14  
15  
16  
17  
18

## 19 **Data management**

20 Data and all appropriate documentation will be stored for a minimum of 10 years after the completion of the  
21 study. This is to enable subsequent analyses with new network analysis techniques as they are developed. All  
22 study data will be stored, analysed and published in anonymised format. Fluid biomarkers will be stored at UCL  
23 and neuroimaging data at Imperial College London.  
24  
25  
26  
27  
28  
29

30 As part of a large European multi-centre study of clinical outcomes following TBI, pseudonymised clinical data  
31 will be shared with the CREATIVE network. The research program of CREATIVE has a strong emphasis on  
32 data collection, aimed at obtaining all available relevant clinical data of the patients admitted to the major trauma  
33 centres in the CREATIVE network, in this instance, all patients admitted to participating MTCs in London.  
34 Data to be collected on these patients will include pseudonymised follow-up data, related to post-acute patient  
35 care and patient outcomes. The pseudonymised data will be uploaded to an encrypted database on a network  
36 which is accessible to the CREATIVE team. This database has full https encryption with a certificate from an  
37 official authority. Both the database and the application into which the data are loaded are run from dedicated  
38 servers. The data collected for this component of the study will be centrally stored by the CREATIVE team for  
39 20 years from the closing date of the study. At that time point, all data collected for this study will be definitively  
40 deleted. If these data are considered at that time to be particularly relevant for scientific purposes, a specific  
41 authorisation to continue their use will be issued to the competent local/national relevant ethical boards/bodies.  
42  
43  
44  
45  
46  
47  
48  
49  
50

## 51 **ETHICS AND DISSEMINATION**

### 52 **Ethical considerations**

53 The relevant ethical approvals have been granted by the following ethics committees: in London, by the  
54 Camberwell St Giles Research Ethics Committee; in Policlinico (Milan), by the Comitato Etico Milano Area 2;  
55  
56  
57  
58  
59  
60

1 in Niguarda (Milan), by the Comitato Etico Milano Area 3; in Careggi (Florence), by the Comitato Etico  
2 Regionale per la Sperimentazione Clinica della Regione Toscana, Sezione area vasta centro; in Trento, by the  
3 Trento Comitato Etico per le Sperimentazioni Cliniche, Azienda Provinciale per i Servizi Sanitari della Provincia  
4 autonoma di Trento; in Lausanne, by the Commission cantonale (VD) d'éthique de la recherche sur l'être humain  
5 (CER-VD); in Ljubljana, by the National Medical Ethics Committee at the Ministry of Health of the Republic of  
6 Slovenia.  
7  
8  
9

10  
11  
12 Periods of post-traumatic amnesia (PTA) or low consciousness level are commonly observed after TBI, and  
13 during this period, patients may not have mental capacity give valid informed consent. An important element of  
14 the proposed work cannot otherwise be answered by only studying patients with capacity.  
15  
16

17  
18  
19 The proposed investigation methods are routinely used in the assessment of TBI patients in an intensive care  
20 setting and are safe, as long as normal safety precautions are taken in the case of MRI. We have used this safely  
21 to investigate the causes of poor clinical outcome after TBI.  
22  
23

24  
25  
26 At the time of initial contact by the clinical team an assessment of the patient's capacity will be made in relation  
27 to entering the study in accordance with national legislation. If the patient is not found to have capacity then they  
28 will be enrolled, if appropriate, following the national rules. Patients will not be coerced if assent is not given. If  
29 during the study the patient subsequently objects to participation in a portion of the study s/he will be withdrawn.  
30  
31  
32 Advanced statements regarding participation in research will be sought and respected.  
33  
34

35  
36  
37 When the patient is no longer in post-traumatic amnesia or a state of impaired consciousness, we will repeat the  
38 consent procedure and the patient will be free to withdraw from the study or continue participation.  
39  
40

41  
42  
43 Our study will involve negligible risk to the patient and will not significantly interfere with freedom of action or  
44 privacy or be unduly invasive or restrictive. The primary inconvenience to the patient is to cooperate with an  
45 MRI scan which can take up to 60 minutes and, for some patients, be noisy, uncomfortable and claustrophobic.  
46 We will consider using light oral sedation such as benzodiazepines (diazepam) if this is judged to be helpful.  
47  
48  
49 There is also a risk to patients if they have ferromagnetic metal on their person and all the usual MRI safety  
50 checks and procedures will be undertaken to minimise this risk. Uncooperative and unconscious patients at the  
51 time of MRI (e.g. intensive care treated patients) will receive sedation and will be monitored for vital signs under  
52 the surveillance of the treating physician and according to local protocols for MRI in critically ill patients.  
53  
54  
55

## 56 **Dissemination**

57  
58  
59  
60

1 The study findings will be disseminated to patients, healthcare professionals, academics and policymakers  
2 including through presentation at conferences and peer-reviewed publications. Data will be shared with approved  
3 researchers to provide further insights for patient benefit.  
4  
5

## 6 **PATIENT AND PUBLIC INVOLVEMENT**

7

8 Patients and research participants were involved in the formulation of our programme via regular participant  
9 involvement events at the sponsoring institution (Imperial College London).  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

## 1 ACKNOWLEDGEMENTS

2  
3 The investigators would like to acknowledge the kind support of our patients and healthy volunteers for taking  
4 part in the study, as well as our funders and all those involved in facilitating the project.  
5  
6

## 7 CONFLICTS OF INTEREST

8  
9  
10 HZ has served at advisory boards for Eli Lilly, Roche Diagnostics and Pharmasum Therapeutics, and is a co-  
11 founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the  
12 University of Gothenburg. The other authors have no potential conflicts to declare.  
13  
14  
15

## 16 DATA STATEMENT

17  
18  
19 BIO-AX-TBI data will be made available in an anonymised form for other approved researchers to use on  
20 completion of the study.  
21  
22

## 23 AUTHOR CONTRIBUTIONS

24  
25  
26 NG, KZ and DJS drafted the manuscript. GB, SM, MO, HZ, FM, DN, AH, JF, AC, EF, EG, SA, PG and AB  
27 critically reviewed and revised it. All authors contributed to the design, intellectual content and approved the  
28 final version.  
29  
30  
31

## 32 ACKNOWLEDGEMENTS

33  
34  
35 We thank the patients who contributed to design of our research programme via regular participation events at  
36 Imperial College London.  
37  
38

## 39 FUNDING

40  
41  
42 The study is funded by the ERA-NET Neuron Cofund (grant MR/R004528/1), part of the European Research  
43 Projects on External Insults to the Nervous System call, within the Horizon 2020 funding framework. The work  
44 was supported by an Alzheimer's Research UK Clinical Research Fellowship awarded to NG, and by the UK  
45 Dementia Research Institute (DRI) Care Research and Technology Centre (NG/DJS), an National Institute of  
46 Health Research (NIHR) Professorship (NIHR-RP-011-048) awarded to D.J.S. and by the NIHR Clinical  
47 Research Facility and Biomedical Research Centre (BRC) at Imperial College Healthcare NHS Trust. The  
48 research was also supported the Medical Research Council through a Clinician Scientist Fellowship awarded to  
49 D.J.S.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## FIGURE LEGENDS

### Figure 1. Recruitment Status

Cumulative number of patients recruited into the BIO-AX-TBI study since its initiation, a total of 311 participants as of June 2020.

## REFERENCES

1. Whitnall L, McMillan TM, Murray GD, et al. Disability in young people and adults after head injury: 5-7 year follow up of a prospective cohort study. *J Neurol Neurosurg Psychiatry* 2006;77(5):640-5. doi: 10.1136/jnnp.2005.078246 [published Online First: 2006/04/15]
2. Thornhill S, Teasdale GM, Murray GD, et al. Disability in young people and adults one year after head injury: prospective cohort study. *Bmj* 2000;320(7250):1631-5. doi: 10.1136/bmj.320.7250.1631 [published Online First: 2000/06/16]
3. Thurman DJ, Alverson C, Dunn KA, et al. Traumatic brain injury in the United States: A public health perspective. *J Head Trauma Rehabil* 1999;14(6):602-15. doi: 10.1097/00001199-199912000-00009 [published Online First: 2000/02/15]
4. Salmond CH, Menon DK, Chatfield DA, et al. Diffusion tensor imaging in chronic head injury survivors: correlations with learning and memory indices. *Neuroimage* 2006;29(1):117-24. doi: 10.1016/j.neuroimage.2005.07.012 [published Online First: 2005/08/09]
5. Kinnunen KM, Greenwood R, Powell JH, et al. White matter damage and cognitive impairment after traumatic brain injury. *Brain* 2011;134(Pt 2):449-63. doi: 10.1093/brain/awq347 [published Online First: 2011/01/05]
6. Scheid R, Walther K, Guthke T, et al. Cognitive sequelae of diffuse axonal injury. *Arch Neurol* 2006;63(3):418-24. doi: 10.1001/archneur.63.3.418 [published Online First: 2006/03/15]
7. Sidaros A, Engberg AW, Sidaros K, et al. Diffusion tensor imaging during recovery from severe traumatic brain injury and relation to clinical outcome: a longitudinal study. *Brain* 2008;131(Pt 2):559-72. doi: 10.1093/brain/awm294 [published Online First: 2007/12/18]
8. Sharp DJ, Bonnelle V, De Boissezon X, et al. Distinct frontal systems for response inhibition, attentional capture, and error processing. *Proc Natl Acad Sci U S A* 2010;107(13):6106-11. doi: 10.1073/pnas.1000175107 [published Online First: 2010/03/12]
9. Bonnelle V, Ham TE, Leech R, et al. Salience network integrity predicts default mode network function after traumatic brain injury. *Proc Natl Acad Sci U S A* 2012;109(12):4690-5. doi: 10.1073/pnas.1113455109 [published Online First: 2012/03/07]
10. Shahim P, Gren M, Liman V, et al. Serum neurofilament light protein predicts clinical outcome in traumatic brain injury. *Scientific reports* 2016;6:36791. doi: 10.1038/srep36791 [published Online First: 2016/11/08]
11. Thelin E, Al Nimer F, Frostell A, et al. A Serum Protein Biomarker Panel Improves Outcome Prediction in Human Traumatic Brain Injury. *J Neurotrauma* 2019;36(20):2850-62. doi: 10.1089/neu.2019.6375 [published Online First: 2019/05/11]
12. Hossain I, Mohammadian M, Takala RSK, et al. Early Levels of Glial Fibrillary Acidic Protein and Neurofilament Light Protein in Predicting the Outcome of Mild Traumatic Brain Injury. *J Neurotrauma* 2019;36(10):1551-60. doi: 10.1089/neu.2018.5952 [published Online First: 2018/11/30]

- 1 13. Bernick C, Zetterberg H, Shan G, et al. Longitudinal Performance of Plasma Neurofilament Light and Tau in  
21 Professional Fighters: The Professional Fighters Brain Health Study. *J Neurotrauma* 2018;35(20):2351-  
32 56. doi: 10.1089/neu.2017.5553 [published Online First: 2018/04/04]
- 4 14. Shahim P, Tegner Y, Marklund N, et al. Neurofilament light and tau as blood biomarkers for sports-related  
5 concussion. *Neurology* 2018;90(20):e1780-e88. doi: 10.1212/WNL.0000000000005518 [published  
6 Online First: 2018/04/15]
- 7 15. Kuhle J, Barro C, Andreasson U, et al. Comparison of three analytical platforms for quantification of the  
8 neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and  
9 Simoa. *Clin Chem Lab Med* 2016;54(10):1655-61. doi: 10.1515/cclm-2015-1195 [published Online First:  
10 2016/04/14]
- 11 16. Magnoni S, Esparza TJ, Conte V, et al. Tau elevations in the brain extracellular space correlate with  
12 reduced amyloid-beta levels and predict adverse clinical outcomes after severe traumatic brain injury.  
13 *Brain* 2012;135(Pt 4):1268-80. doi: 10.1093/brain/awr286 [published Online First: 2011/11/26]
- 14 17. Magnoni S, Mac Donald CL, Esparza TJ, et al. Quantitative assessments of traumatic axonal injury in human  
15 brain: concordance of microdialysis and advanced MRI. *Brain* 2015;138(Pt 8):2263-77. doi:  
16 10.1093/brain/awv152 [published Online First: 2015/06/19]
- 17 18. Bouzat P, Sala N, Suys T, et al. Cerebral metabolic effects of exogenous lactate supplementation on the  
18 injured human brain. *Intensive care medicine* 2014;40(3):412-21. doi: 10.1007/s00134-013-3203-6  
19 [published Online First: 2014/01/31]
- 20 19. Maas AI, Harrison-Felix CL, Menon D, et al. Common data elements for traumatic brain injury:  
21 recommendations from the interagency working group on demographics and clinical assessment. *Arch*  
22 *Phys Med Rehabil* 2010;91(11):1641-9. doi: 10.1016/j.apmr.2010.07.232 [published Online First:  
23 2010/11/04]
- 24 20. Maas AIR, Menon DK, Adelson PD, et al. Traumatic brain injury: integrated approaches to improve  
25 prevention, clinical care, and research. *Lancet Neurol* 2017;16(12):987-1048. doi: 10.1016/S1474-  
26 4422(17)30371-X [published Online First: 2017/11/11]
- 27 21. Malec JF, Brown AW, Leibson CL, et al. The mayo classification system for traumatic brain injury severity. *J*  
28 *Neurotrauma* 2007;24(9):1417-24. doi: 10.1089/neu.2006.0245 [published Online First: 2007/09/26]
- 29 22. Apolone G, Brazzi L, Pesce C. Multicenter study on the treatment and outcome of patients admitted to  
30 intensive care units in Italy. Presentation of the research project and the study protocol. GiViTI  
31 (Gruppo Italiano per la Valutazione degli interventi in Terapia Intensiva). *Minerva Anestesiol*  
32 1992;58(12):1297-303. [published Online First: 1992/12/01]
- 33 23. Escott-Price V, Sims R, Bannister C, et al. Common polygenic variation enhances risk prediction for  
34 Alzheimer's disease. *Brain* 2015;138(Pt 12):3673-84. doi: 10.1093/brain/awv268 [published Online  
35 First: 2015/10/23]
- 36 24. Oddo M, Hutchinson PJ. Understanding and monitoring brain injury: the role of cerebral microdialysis.  
37 *Intensive Care Med* 2018;44(11):1945-48. doi: 10.1007/s00134-017-5031-6 [published Online First:  
38 2017/12/25]
- 39 25. Giorgi-Coll S, Thelin EP, Lindblad C, et al. Dextran 500 Improves Recovery of Inflammatory Markers: An In  
40 Vitro Microdialysis Study. *J Neurotrauma* 2020;37(1):106-14. doi: 10.1089/neu.2019.6513 [published  
41 Online First: 2019/07/13]
- 42 26. Cole JH, Jolly A, de Simoni S, et al. Spatial patterns of progressive brain volume loss after moderate-severe  
43 traumatic brain injury. *Brain* 2018;141(3):822-36. doi: 10.1093/brain/awx354 [published Online First:  
44 2018/01/09]
- 45 27. Scott G, Zetterberg H, Jolly A, et al. Minocycline reduces chronic microglial activation after brain trauma  
46 but increases neurodegeneration. *Brain* 2018;141(2):459-71. doi: 10.1093/brain/awx339 [published  
47 Online First: 2017/12/23]
- 48 28. Jolly AE, Balaet M, Azor A, et al. Detecting axonal injury in individual patients after Traumatic Brain Injury.  
49 *Brain* in Press
- 50 29. Cetin Karayumak S, Bouix S, Ning L, et al. Retrospective harmonization of multi-site diffusion MRI data  
51 acquired with different acquisition parameters. *Neuroimage* 2019;184:180-200. doi:  
52 10.1016/j.neuroimage.2018.08.073 [published Online First: 2018/09/12]

- 1 30. Sharp DJ, Beckmann CF, Greenwood R, et al. Default mode network functional and structural connectivity  
2 after traumatic brain injury. *BRAIN* 2011;134:2233-47. doi: brain/awr175
- 3 31. Monteiro M, Newcombe VFJ, Mathieu F, et al. Multiclass semantic segmentation and quantification of  
4 traumatic brain injury lesions on head CT using deep learning: an algorithm development and  
5 multicentre validation study. *The Lancet Digital Health* 2020;2(6):e314-e22. doi: 10.1016/S2589-  
6 7500(20)30085-6


7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26

For peer review only



For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>